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DNA nanotechnology was used to interface with proteins through DNA-
protein hybrid molecules for protein detection and protein intracellular delivery. EZZ 
protein, which can bind to almost all IgG antibodies, was selected to be conjugated to 
DNA linker. Different methods of DNA-protein conjugation were used to develop 
universal adapters between IgG antibodies and DNA. Using DNA nanobarcodes, 
which is based on the color ratios of two colors rather than using different colors, a 
library of IgG-based nanobarcodes were generated through a simple mixing step. The 
IgG-based nanobarcodes were used as a platform to simultaneously detect target 
proteins in different systems, including microbead-based, membrane-based, and 
tissue-based. Moreover, for the first time, a new concept of using DNA transfection 
reagents was introduced to deliver proteins intracellularly with great efficiency.  
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CHAPTER 1: INTRODUCTION 
 
The concept of bringing two or more different materials to work together, to 
create so-called “hybrid” materials with new characteristics and applications, is an 
interesting and exciting development in materials science. This work will describe 
how DNA and protein are brought together to serve as one material, with the 
properties, advantages, and functions of both nucleic acid and protein. In addition, I 
will describe applications of DNA-protein hybrid materials, as well as discuss the 
potential of the field.  
 The structure of the dissertation includes six chapters. Chapter 1 will introduce 
the background for a general understanding about this work and related fields 
including DNA nanotechnology, DNA-protein conjugation, protein detection, and 
protein delivery. Chapter 2 and 3 will talk about the different methods of making 
DNA-protein hybrid materials, and their characterization. Chapter 4 and 5 will focus 
on the applications of protein detection and protein delivery, respectively. Finally, 
Chapter 6 will wrap up with conclusions and open up to discussions and future 
directions. 
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1.1. DNA As Generic Materials For Nanotechnology  
DNA has been well known as the genetic material of life since it was first 
discovered. However, since the early 1980s, Seeman introduced a new concept of 
using DNA as a generic material, creating rigid, artificial branched DNA junctions
1
 as 
building blocks to construct geometrical DNA nanostructures
2, 3
. Using the most basic 
and important property of DNA, Watson-Crick base pairing, Seeman and his group 
produced unnatural two, three, four-armed branched DNA junctions using double-
crossover (DX)
4
, triple-crossover (TX)
5
, and paranemic-crossover (PX)
6
 motifs. 
Inspired by these motifs, additional designs such as parallelograms
7
, four-by-four-
structures
8
, and three-, five-, and six-point star motifs
9-11
 have been developed and 
assembled into 2D nanoarrays 
12-14
, 3D-nanoarrays
15-17
, and DNA nanodevices
18, 19
, as 
shown in Figure 1.1. More recently, Rothemund has presented the “DNA origami” 
concept (Figure 1.2) as a novel approach to create arbitrary patterns, such as a star or 
smiley face
20
. Later, DNA origami became widely used to form more complicated 
structures
21, 22
 or a DNA box with a controlled lid
23
. For more details about recent 
developments in structural DNA nanotechnology, please read the excellent reviews 
18, 
24-28
. 
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Figure 1.1. General motifs of structural DNA nanotechnology. (a-f) 2D DNA 
nanostructures formed from double-crossover (DX)
12
, three-point-star
9
, T-junction
29
, 
four-by-four junction
8
, five-point-star
10
, and six-point-star motifs
11
, respectively. (g) 
The first 3D DNA octahedron nanostructure assembled by DX motifs.
30
 (h) Hollow 
polyhedron 3D structures assembled by three-point-star motifs.
17
 (i) The first 3D DNA 
crystal (bottom) formed by the tensegrity triangle (top).
16
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Figure 1.2. DNA origami. (a) 2D DNA nanostructures made by DNA origami. (b-c) 
3D DNA origami
21, 22
. (d) DNA box based on DNA origami.
23
  
 
However, in general, structural DNA nanotechnology has existed as a mostly 
academic pursuit. In contrast, taking advantage of molecular biology toolkits, Luo and 
his group has brought “biology to materials”31 and can be considered as one of the first 
groups to use branched DNA building blocks for biological and biomedical 
applications. Unlike Seeman and other research groups who are using complicated 
DX, TX, or DNA origami in their work, Luo has focused on the simple double helix 
DNA structure to build Y-shaped and X-shaped DNA molecules (Figure 1.3 a) as the 
building blocks for multifunctional materials. Moreover, using ligase to “glue” Y- or 
X-monomers together, rather than just based on nucleic acid hybridization
32, 33
, Luo 
5 
 
and coworkers have formed stable dendrimer-like (DL) DNA
34
, and DNA hydrogel
35
, 
which later were used as DNA nanobarcodes for multiplexed DNA detection
36
 (Figure 
1.3 b), and in a DNA hydrogel for cell-free protein production (“P-gel”)35, 37 (Figure 
1.4), respectively. More recently, as an alternative to ligase, they have used 
photocrosslinker-modified DNA to generate DNA nanospheres for drug delivery
38
. 
Moreover, attaching different functional moieties to the molecular branched building 
blocks, they created multifunctional nanoarchitectures from anisotropic, branched and 
crosslinkable building blocks (ABC monomers)
39
 (Figure 1.3b). This material was 
utilized in a pathogen detection system in which photo-polymers were generated only 
in the presence of a specific DNA sequence, and was also used as a biocompatible 
nanovector to deliver both drugs and tracers simultaneously. In addition to interacting 
with biological systems, DNA could also be used to interact with non-biological 
systems such as gold nanoparticles, allowing for enhanced control of the self-assembly 
of highly ordered nanoparticle arrays
40-42
. 
In summary, DNA is an excellent material for a range of applications due to its 
many unique properties. As mentioned above, Watson-Crick base pairing is highly 
sequence specific, which makes DNA hybridization rationally designable and 
programmable. Another great property of DNA is its precisely controlled dimensions 
at the nanoscale, so it can be produced with the exact length as desired. One base is 
about 0.34 nm in length and 2 nm in diameter, and the helical periodicity of double 
helix DNA is 10–10.5 nucleotide pairs, or 3.5 nm per turn. Moreover, unlike most 
polymers or other soft materials, DNA has a persistent length of 50 nm or 1 nm for 
double stranded or single stranded DNA, respectively, so by simply adjusting the 
6 
 
number of base pairs to tune the length, we can get either a rigid or flexible fragment 
of DNA. In addition, our work takes advantage of molecular biology toolkits to 
manipulate DNA. DNA can be cut specifically, chopped nonspecifically, linked, or 
amplified by more than 4000 different enzymes, including restriction enzymes, 
nucleases, ligases, and polymerases. Furthermore, DNA is non-toxic, biocompatible, 
and biodegradable. Finally, DNA can be modified with variety of chemical groups, 
nanoparticles, polymers, fluorophores, or (as the main focus of this dissertation) 
proteins. Combining all of these properties above makes DNA not only a unique 
material in and of itself, but also excellent for using with other materials.  
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Figure 1.3. DNA as generic materials. (a) X-DNA, Y-DNA building blocks. (b) 
Dendrimer-like DNA based DNA nanobarcodes for multiplexed DNA detection.
36
 (c) 
Target-driven polymerization of ABC monomers for multiplexed DNA detection.
39
  
 
Figure 1.4. Protein-producing DNA hydrogel (“P-gel”)37. The plasmid is incorporated 
into a DNA hydrogel matrix which shows greater expression of protein in a cell lysate, 
compared to conventional method (“SPS”) of using only gene with cell lysate.  
 
 
1.2. DNA Protein Hybrid Nanostructures 
As mentioned above, DNA nanotechnology has been the core of many 
achievements of our lab. One of our goals is to explore novel uses of DNA, either by 
itself or combined with other materials to explore applications in many areas, 
including biomedicine, biological and biomedical diagnosis, environmental 
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monitoring, food safety, and materials. It would be extremely useful for these 
applications if we could interface our DNA structures with proteins. Proteins have a 
large spectrum of functions, from enzymatic activities, signal transduction, gene 
regulation to structural or mechanical functions. However, it is more challenging to 
modify proteins directly, compared to DNA, due to their relative instability and 
incompatibility with many chemical reagents or buffers. As discussed above, DNA 
can be easily controlled and manipulated; therefore, using DNA technology not only 
gives us more tools to work with proteins, but also allows us to interface proteins into 
bio and non-bio systems. In other words, combining proteins and DNA together would 
create new materials with new properties and functions.  
DNA-protein hybrid materials have been mostly used for detection and for the 
assembly of biomolecular nanostructures. Due to the presence of two functional 
moieties, they have the advantages of interfacing with both nucleic acids and proteins 
at the same time. For example, in bioanalytic systems, one component could be used 
as the probe, and the other could serve as the reporter. Therefore, DNA-protein hybrid 
materials could be used for the detection of either DNA or proteins. For DNA 
analysis, enzymes such as alkaline phosphastase (AP)
43
, horseradish peroxidase 
(HRP)
44, β-galactosidase45, lipase46, or esterase47 have been used as signal amplifiers. 
For protein analysis, DNA has served as the reporters, and many innovative assays 
have been developed by taking advantage of DNA technologies such as PCR
48
, 
RCA
49-51
, and DNA microarrays
52-57
. Protein detection using DNA-protein conjugates 
will be discussed more below since it is one of the main focuses of this dissertation. 
For more details on other applications using DNA-protein conjugates, please read 
9 
 
these reviews.
58-62
 
For the development of DNA-protein conjugation, many methods have been 
established to construct DNA-protein conjugates, either non-covalently or covalently. 
Table 1.1 summarizes some of the most current and widely used methods for DNA-
protein conjugation. Depending on the purpose, either non-covalent or covalent 
approaches may be selected as the most appropriate. Non-covalent methods are 
relatively fast and easy, but can be disrupted by high temperature or denaturing 
conditions, and can also generate multiple DNA strands on one protein after the 
conjugation. This dissertation focuses primarily on covalent conjugation between 
DNA and proteins, particularly at a 1:1 molar ratio between DNA and protein for 
controlling the stoichiometry and geometry of the proteins by DNA.  
 
Table 1.1. Summary of methods for DNA-protein conjugation 
Non-covalent Coupling Covalent Coupling 
1. Biotin-(strept)avidin Interaction 
2. Ni-NTA-Hexahistidine Interaction 
3. Aptamers 
4. Reconstitution of Apoenzymes 
 
1. Bioconjugation Chemistry 
 Thiol  
 Amine 
 Carboxyl 
2. Bioorthogonal Chemistry 
 “Expressed Protein Ligation” (EPL) 
 SNAP tag, CLIP tag, and HaloTag 
 “Click” chemistry 
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For non-covalent approaches, the most commonly used method is the biotin-
streptavidin/avidin interaction. Despite its noncovalent bonding, the biotin-
streptavidin/avidin interaction has an enormously high affinity with a disassociation 
constant Kd of about 10
14
 mol/L, which make it one of the strongest noncovalent 
bonds known in nature
63
. Also, there are a large number of biotin derivatives 
commercially available and mild biotinylation procedures make it one of the first 
choices to make DNA-protein conjugates. However, streptavidin exists as a tetramer. 
Four monomeric streptavidin proteins interacting with four biotin molecules makes it 
difficult, if not impossible, to control the stoichiometry of the resulting DNA–protein 
conjugates, and therefore it may not be used for the rational one-to-one construction of 
nanodevices. Also, streptavidin-biotin interactions can be disrupted by high 
temperature. Other non-covalent methods that have been used for protein-DNA 
conjugation are Ni-NTA-hexahistidine interaction
64-67
, aptamers
68, 69
, and some 
specific apoenzymes
70, 71
. Unlike biotin-streptavidin binding, Ni-NTA-polyhistidine- 
and aptamer-based conjugation strategies have much weaker affinities, in the 
nanomolar (nM) to micromolar (µM) range of Kd, which is approximately a million 
times lower than the biotin-streptavidin affinity. Moreover, Ni-NTA-polyhistidine 
interaction can be easily broken by the addition of a nickel chelator, such as EDTA or 
imidazole, and high temperatures will also destroy the binding between aptamers and 
their ligands.  
 For covalent methods, there are two big categories of chemistry and 
biochemistry reactions: bioconjugation methods, and bioothorgonal conjugation 
methods. The first group mostly utilizes the chemical reactions between thiol, amine, 
11 
 
carboxyl, and carbonyl groups which are available or can be easily modified onto 
proteins and DNA. The Thermo Scientific Pierce Crosslinking Technical Handbook is 
a good reference for choosing the chemistry and the crosslinkers for protein-DNA 
conjugation. Table 1.2 summarizes some of the commonly-used bifunctional 
crosslinkers. As implied in the name, bifunctional crosslinkers contain two functional 
groups which could crosslink two of the same chemical group (homo-bifunctional 
crosslinkers) or two different chemical groups (hetero-bifunctional crosslinkers) to 
generate DNA-protein hybrid molecules. Many homo-bifunctional crosslinkers are 
used to conjugate amine-to-amine or sulfhydryl-to-sulfhydryl groups, and these 
crosslinkers mostly utilize the N-Hydroxysuccinimide (NHS) ester or maleimide 
derivatives, respectively. For hetero-bifunctional crosslinkers, there are more choices 
to crosslink different groups with each other: for example, amine-to-sulfhydryl, 
amine-to-carboxyl, or sylfhydryl-to-carbonyl (aldehydes and ketones) groups.  
Table 1.2. Commonly-used bifunctional crosslinkers
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Although there are many choices for bioconjugation methods to form DNA-
protein conjugates, these methods frequently require mutually exclusive reaction 
conditions that are incompatible with each other, or not suitable for cellular 
conditions. In contrast, bioorthogonal conjugation methods can overcome this 
limitation.  The term bioorthogonal chemistry refers to any chemical reaction that can 
occur inside of living systems without interfering with native biochemical processes. 
This group involves enzymes, which self-catalyze specific substrates that can be pre-
modified on DNA, and more currently “click” chemistry, a concept that mimics nature 
to generate substances quickly and reliably by joining small modular units. For 
enzyme approaches, the proteins of interests (POI) have to be cloned with the enzymes 
before the catalytic reactions happen between the enzymes and modified DNA 
substrates. For convenience, several kits for cloning POI with the enzyme tags are 
commercially available. The first example is the IMPACT (Intein Mediated 
Purification with an Affinity Chitin-binding Tag) Kit (New England BioLabs). This is 
also known as “expressed protein ligation” (EPL). In this method, the POI is 
recombinant with a protein domain called INTEIN and a chitin binding (CBD) 
domain. CBD binds to chitin-modified beads or columns to purify the protein 
complex. The intein domain causes an acyl shift between the target protein and itself 
to form a thioester group which can be cleaved by adding a small molecule compound 
such as mercapto-ethane-sulfonic acid to release the target protein from the column. 
This step generates the C-terminal thioester of the POI, which is then ligated with 
cysteine-modified nucleic acid as described in Figure 1.5 a. The EPL method is 
advantageous over conventional cross-linking techniques because it allows DNA–
13 
 
protein conjugates to be readily prepared with well-defined stoichiometric 
composition and regiospecific linkage.
72-77
  
Another self-labeling protein that is adapted to widely use for protein-DNA 
conjugation is called the SNAP tag (New England BioLabs, Ipswich, MA). The SNAP 
protein is a 20 kDa mutant of the DNA repair protein O
6
-alkylguanine-DNA 
alkyltransferase (hAGT), which can react with benzylguanine (BG) substrates to form 
a stable covalent thioether bond. SNAP tag was one of the methods used in the work; 
therefore, it will be discussed later in greater detail. Similarly, a sibling of the SNAP 
tag is the CLIP tag, also a mutant form of hAGT, which reacts specifically and rapidly 
with O2-benzylcytosine (BC) derivatives (Figure 1.5 b). The New England Biolabs 
website contains a list of publications using SNAP tag and CLIP tag with useful 
information about the systems and their applications. More recently, HaloTag Protein 
(Promega, Madison, WI) has been developed for bioorthogonal protein-DNA 
conjugation with the advantage of having many different HaloTag Ligand Building 
Blocks (Promega Corporation, Madison, WI) that can be modified with DNA using 
amine or thiol chemistry. Similar to the SNAP tag and CLIP tag, the HaloTag is a 
modified haloalkane dehalogenase which catalyzes conjugation specifically and 
covalently to chloroalkane derivatives (Figure 1.5 c).
78, 79
  
In another approach, different from self-ligation proteins which lack turnover 
activity and remain linked to the products after the reaction, a new enzyme with true 
catalytic activity called sortase has been utilized to form covalent DNA-protein 
conjugates. Sortase is also a method used in this work, so it will be discussed in more 
detail in the next chapter.  
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Figure 1.5. Mechanisms of self-labeling proteins. a) Expressed protein ligation system 
(“EPL”),  b) SNAP tag, CLIP tag, and c) Halo tag. (Pictures a, b, c are obtained from 
reference 
59
, New England Biolabs and Promega websites, respectively.) 
 
Recently, “click” chemistry with several types of reactions have emerged in 
the applications of biomedical researches.
80-84
 Among the “click reactions”, the 
copper(I)-catalyzed Huisgen 1,3-dipolar cycloaddition of azides and alkynes 
(CuAAC)
83, 85-87
 has proven to be a versatile methods for the modification of synthetic 
DNA oligonucleotides. Currently copper-free method
88
 is also widely used. Normally, 
for DNA-protein conjugation using “click” reactions, DNA oligonucleotides are 
modified with alkyne groups which are commercially available, and proteins are 
15 
 
modified with azide groups. However, in order to modify azide groups onto the 
proteins, azide-modified compounds (for example, sugars
89
 and amino acids
90
) are 
incubated with cultured cells. Azido-sugars are metabolically incorporated into cell 
surface O-linked glycoproteins through the oligosaccharide biosynthesis pathway. For 
other proteins that are not glycoproteins, azide-modified amino acid analogs are fed to 
cultured cells and incorporated into proteins during active protein synthesis. These 
approaches, therefore, cannot generate a 1:1 molar ratio conjugation between DNA 
and protein, unlike several of the enzyme-based approaches. On the other hand, 
“click” chemistry has become very effective in producing short polypeptide-DNA 
conjugates
91-93
 since it is simpler to directly modify the azide groups onto short 
polypeptides.  
 
1.3. Protein Detection 
Although there are a large number of tools for nucleic acid analysis, there are 
fewer tools for protein detection due to the complicated and varied physical and 
chemical properties of proteins. In this section, I will briefly introduce some common 
methods and materials used for protein detection as a general background for the 
development of the field. Traditionally, proteins are detected by enzyme-linked 
immunosorbent assay (ELISA) 
94
 or western blotting (WB)
95
 techniques, which were 
developed in early 1970s and 1980s, respectively. For ELISA methods, a target 
protein is captured by an antibody then sandwiched with a second antibody that 
incorporates a catalytic, signal-generating entity. Nowadays, there are a wide variety 
of complete ELISA kits commercially available for measuring intracellular and 
16 
 
extracellular proteins using different types of detection signals including colorimetric, 
fluorescent, and chemiluminescent. To detect protein by WB, the protein targets are 
separated from the others by gel electrophoresis (1D or 2D) before being transferred to 
a membrane where they are detected by specific antibodies. The primary antibodies 
could be directly conjugated with fluorophores or recognized by secondary antibodies 
carrying enzymes or dyes to generate colorimeric, chemiluminescent, or fluorescent 
signals. This is an effective and useful method to detect and characterize specific 
proteins in a complex mixture of proteins. Similar to ELISA, many WB kits are 
commercially available with a variety of signal detection systems. Among the choices 
for detection signals, fluorescence-based detection strategies are increasingly used, 
with approximately 3,000 fluorescent probes available over a broad spectral range 
allowing simultaneous imaging of multiple components at the intercellular or 
intracellular levels.
96
 
Adapting from the ELISA concept, high throughput protein planar and bead-
based microarrays provide powerful multiplexed approaches to identify protein 
targets, or protein-protein interactions.
97-100
 However, there are many challenges in 
protein microarray developments due to the structural diversity and complexity of 
proteins. Proteins are highly sensitive to the physiochemical properties of the chip 
support materials. Moreover, issues with low polarity, solubility, and incompatible 
surface chemistries promote the retention of proteins, cause denaturation, or result in 
improper folding leading to loss in biological activity 
101-103
. To overcome these 
challenges, DNA microarrays which are more stable, easier to make, and are more 
well developed to build protein arrays using DNA protein binding domains
104, 105
 or 
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DNA-protein conjugates
106-109
 have been considered as an alternative approach (Figure 
1.6 a). Furthermore, with the advantage of having two functional moieties in one 
molecule, DNA-protein conjugates were used to detect proteins by using polymerase 
chain reaction (PCR) technology to amplify the signal of the protein targets
50, 110-115
. 
The novel concept was introduced as immuno-PCR (iPCR) technique (Figure 1.6 b) 
by Sano et al. in 1992
48
. This target-based amplification strategy is much more 
sensitive, about 1,000-10,000 fold, than signal-based amplification methods such as 
ELISA. Later, instead of using PCR, the immuno-PCR technique was adapted to use 
another DNA amplification technique called rolling circle amplification (RCA) to 
visualize endogenous proteins on cells using an isothermal process  (Figure 1.6 c).
49, 50
 
Recently, proximity ligation, a technique developed from ELISA and immuno-PCR 
concepts, which was introduced by Landegren et al. in 2002, are widely used for the 
detection of proteins with high sensitivity at zeptomole (40 x 10
-21)
 amount. 
116-125
 In 
this method, basically, the protein targets are sandwiched between two antibodies-
DNA conjugates, enabling hybridization with a DNA probe for signal amplification by 
PCR due to their close proximity (Figure 1.6 d).  
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Figure 1.6. Application of DNA-protein conjugates in analytical systems. a) DNA-
directed hybridization of protein arrays.
54
 b) immuno-PCR by PCR amplification.
48
 c) 
immuno-PCR by RCA amplification
50
. d) proximity ligation.
117
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Recently, with the emergence of nanotechnology, besides the development of 
DNA-protein hybrid materials in protein detection, new materials are used to develop 
novel assays for detecting proteins with higher sensitivity, specificity, and robustness 
(Table 1.3). Nanomaterials with unique and controllable size-dependent properties, 
tunable chemical compositions, and in certain cases chemically and physically robust 
structures
126, 127
 has given rise to new platforms for protein detection. Among those 
materials, gold nanoparticles with high surface-to-volume ratios give the advantage 
that target-binding events are often more easily transduced into detectable signals.
128, 
129
 DNA-functionalized gold nanoparticles have been used to develop different protein 
detection approaches, including aptamers
130, 131
, fluorescent
132, 133
, 
chemiluminescent
134
, and scanometric
135
 strategies. Moreover, due to the unique 
optical and electronic properties of nanoparticles, surface plasmon resonance (SPR)-
based
136-139
, and Raman-spectroscopy-based
140, 141, 141
 methods  have been successfully 
developed to detect protein targets in label-free approaches. Besides gold 
nanoparticles, other nanomaterials such as carbon nanotubes
141, 142
 and silicon 
nanowires
143
 have been explored to provide new detection systems based on changes 
in electrical conductivity in the presence of protein targets.  
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Table 1.3. Detection of protein biomolecules.
128
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1.4. Protein Delivery  
As important as early detection of diseases, delivering proteins and peptides as 
therapeutic modalities to treat human diseases is also essential and attracts a lot of 
attention from researchers and pharmaceutical companies. Many diseases occur from 
the overexpression or alterations in the functions of intracellular proteins. As a result, 
inhibiting those malfunctioned proteins or delivering their active forms to specific 
cells or organs in living organisms is an important goal for many medical applications, 
including cancer therapy, vaccination, regenerative medicine, treating loss-of-function 
genetic disease, and imaging.
144-147
 However, all current protein drugs target only the 
surface of the cells to trigger signaling pathways to affect the real targets 
downstream,
144, 148
 and therefore this is a relatively indirect way to correct the 
functioning of the cell. In order to achieve more direct responses from protein targets 
inside cells to obtain more efficient cures, protein intracellular delivery beyond surface 
delivery is essential. However, there are many issues related to delivery of proteins 
and peptides. Proteins have complicated high order structures, but poor physical, 
chemical, and biological stability. Physical (shear pressure), chemical (pH, 
temperature), or biological (enzyme digestion, immunogenicity) changes of their 
native structures could affect their biological activities. Moreover, unfavorable 
pharmacokinetics, pharmacodynamics, and permeability across biological membranes 
of protein drugs are also significant barriers for intracellular delivery of target 
proteins.  
 
There are two basic focuses in protein delivery research: establishing an 
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effective delivery means and increasing the biological half-life of the protein targets. 
Most native proteins are membrane impermeable due to electrostatic repulsions; 
therefore, appropriate delivery vehicles are required to escort proteins into the cytosol. 
More importantly, the carriers also have to be able to release the proteins after entering 
the cytosol to avoid being degraded from proteolysis or trafficked through 
endomembrane compartments for clearance.
149
 To date, many materials have been 
used to develop efficient carriers for protein intracellular delivery as summarized in 
Table 1.4, which includes peptides, peptide nucleic acid (PNA), lipids, polymers, 
carbon nanotubes, nanoparticles and even proteins. For more details on the current 
development of protein delivery, please read the following reviews.
145-147, 150-152
   
The most commonly used approaches for intracellular protein delivery utilize 
the genetic fusion of the target protein to protein transduction domains (PTDs) or cell-
penetrating peptides (CPPs), such as the HIV-1 transactivator of transcription (TAT) 
peptide, oligoarginines, and the Drosophila Antennapedia-derived penetratin 
peptide.
153-160
 However, these methods have low efficiency in the escape of proteins 
from the endosome to the cytosol, leading to CPP-tagged cargoes sequestered in 
intracellular vesicles.
161-167
 Alternately, lipid-based materials, especially liposomes, 
have been explored intensively for protein delivery since 1970s.
168-172
 Liposomes are 
bilayered vesicles assembled from amphiphilic building blocks, such as lipids or 
phospholipids, which should not be confused with micelles composed of monolayers. 
Liposomes can adhere to plasma membranes and enter the cell via endocytosis or 
liposome-cell fusion
173
. Recently, several lipid-based reagents for protein delivery are 
commercially available; for examples, FuGENE®6 from Roche, BioPORTER® from 
23 
 
Sigma Aldrich, PULSin® from Pulsin, and Pro-Ject™ from Thermo Scientific.  
 
Table 1.4. Summary of materials used for protein intracellular delivery. 
Types of materials Examples 
Peptide-mediated materials Protein to protein transduction domains 
(PTDs)
174-176
 
Cell penetrating peptides (CPPs) 
153-160, 177
 
Peptide nucleic acid (PNA)-
based materials 
PNA oligomer
178, 179
 
Lipid-based materials 
 
Liposomes
168-172
 
Commercial lipid-based reagents: 
BioPORTER™180, PULSin181 
Solid-lipid nanoparticle
182, 183
 
Polymeric materials Polyionic complex (PIC) micelles
184-186
  
PEG, PEI, PLGA, etc.
187
 
{{1206 Shimoni,O. 2012}}
177
 
{{1206 Shimoni,O. 2012}}
187-192
 
Inorganic materials Carbon nanotubes
193, 194
 
Quantum dots
195-199
 
Gold nanoparticles
188, 200-202
 
Mesoporous silica nanoparticles
203-206
 
Magnetic nanoparticles
207-209
 
Protein-mediated materials Superpossitively charged protein
210
 
Engineering protein G
211
 
Virus-like nanoparticle
212
 
 
 
With the advantage of being an extremely versatile class of materials, 
polymers have emerged to develop novel drug delivery systems. The selection and 
design of a polymer to give the desired chemical, interfacial, mechanical and 
biological functions is a challenging task and requires a thorough understanding of the 
24 
 
surface and bulk properties of the polymer.
213
 To help with that, Angelova and 
Hunkeler have proposed a flow chart for rational selection of polymers for biomedical 
applications.
214
 Although this flow chart is intended specifically for polymers, it can 
also provide insight for developing protein delivery systems using other materials.  In 
addition, the interaction between polymers and proteins has been proven to increase 
the systemic circulation of protein drugs which is an important aspect of drug 
delivery.
146, 215
 Many different strategies, such as direct conjugation via either 
chemical modifications
216-219
, physical adsorption and electrostatic interactions
184-186
, 
in situ polymerization
188, 220-223
, emulsion-based
224-227
 and layer-by-layer
228-230
 
encapsulations, can be used to incorporate target proteins with polymers. To date, 
various antibodies, cytokines, and growth factors have been PEGylated
231
 with FDA 
approval for clinical use
232
. Besides PEG, many other polymers, which can be broadly 
classified as biodegradable or non-biodegradable
213
, have been used to enhance the 
biological half-life of protein targets; for examples, poly(N-vinyl pyrrolidone) 
(PVPON)
187
, non-degradable polymer matrices such as poly(lactide-co-glycolide) 
(PLGA)
189
, PEI
190-192
, PPAAc
233
, methylenebisacrylamide or acid-degradable glycerol 
dimethacrylate (Figure 1.7)
188
.  
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Figure 1.7. Single-protein nanocapsules for intracellular protein delivery.
188
 a) 
Schematic showing the synthesis and cellular uptake of cationic single-protein 
nanocapsules with degradable and non-degradable polymeric shells. b) Fluorescence-
assisted cell sorting of HeLa cells incubated with different concentrations of protein 
materials.  
 
Recently, inorganic materials including carbon nanotubes
193, 194
, quantum 
dots
195-199
, gold
188, 200-202
, silica
203-206
, and magnetic particles
207-209
 have also been 
explored for drug, gene, and protein delivery. The high surface area to volume ratio of 
these materials results in improved pharmacokinetics and biodistribution of the 
payload
234, 235
. Their size effects and toxicity on cell uptake have also been 
investigated to obtain a better understanding of the mechanism and rate of cell uptake, 
as well as to better characterize their ability to penetrate through tissue membranes
236-
238
. In addition, taking advantage of molecular biology and protein engineering 
techniques, target proteins can be fused to engineered superpositively charged GFP 
protein, which were extensively mutated at their surface-exposed residues, as a 
delivery vehicle to penetrate cell membranes (Figure 1.8)
210
. Moreover, Lim et al. has 
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developed an engineered protein G system, containing cell penetration peptides and 
polyhistidine tag, in order to combine with Ni-NTA modified nanoparticles for the 
non-invasively delivery of IgG antibodies into cells.
211
  
 
    
Figure 1.8. Comparison of mCherry delivery by +36 GFP, TAT, Arg10, Penetratin. a) 
Flow cytometry of HeLa, BSR, 3T3, PC12, and IMCD cells incubated in the presence 
of specific concentrations of the protein targets. b) Confocal fluorescence microscopy 
of live cells incubated with 100 nM +36 GFP-mCherry for 4h at 37oC.
210
  
 
1.5. Significance of this dissertation  
Although DNA-protein hybrid materials have been developed for many 
applications as discussed above, there are still a lot of potential that has yet to be 
realized with this type of materials. In this work, a protein-DNA hybrid molecule was 
developed to serve as a universal adapter for interfacing between IgG antibodies and 
DNA nanotechnology. For the purposes of protein detection, DNA nanobarcodes were 
used as the reporters for an IgG-based protein detection system with potential for 
multiplexed detection. This system can be used as a versatile platform for protein 
detection due to the capability of detecting proteins in many systems, including bead-
27 
 
based, membrane-based, and tissue-based. Furthermore, and for the first time, DNA-
protein materials were used for intracellular delivery of proteins and IgG antibodies 
using branched DNA as the carrier. Combined with DNA transfection reagents, the 
DNA-assisted protein intracellular delivery (DAPID) system has greatly enhanced the 
efficiency of uptake. This could provide a new route for protein intracellular delivery 
with great efficiency. Furthermore, our system can be easily extended to deliver 
multiple proteins and other biomarkers, as well as moieties beyond proteins including 
but not limited to nanoparticles, lipids, and polymers, as long as they are conjugated 
onto branched DNA. We believe that this DNA-assisted protein intracellular delivery 
(DAPID) system will result in a paradigm shift in drug development and delivery.  
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CHAPTER 2: SYNTHESES OF DNA-PROTEIN CONJUGATES 
 
2.1. Introduction 
As mentioned previously, this dissertation focuses on the use of covalent 
conjugation methods to construct one-to-one molar ratio DNA-protein hybrids for 
controlling the stoichiometry and geometry of the proteins by DNA. Three different 
conjugation methods were explored: SNAP tag, sulfo-SMCC crosslinker, and sortase 
A. (Two other methods were tried without success: “express protein ligation” (EPL), 
and Michael addition chemistry between acrydite and thiol groups.) For all methods, a 
small protein called EZZ (16 kDa) was used to create a DNA-protein hybrid, a 
universal adapter which can interface with both a DNA molecule and an IgG antibody. 
EZZ protein is an engineered version of the native protein A from Staphylococcus 
aureus (SpA).
1
 It contains two repeating Z domains which were engineered based on 
the B domain, and a short signal sequence from the E domain of the native protein A 
to help direct protein expression. Similar to native protein A, EZZ protein possesses 
many interesting properties. For example, it is stable over a broad range of pH (2-12) 
and in the presence of various detergents. It can bind reversibly to a large variety of 
IgGs via the Fc fragment (Table 2.1), and the IgG-EZZ complex can be dissociated 
under controlled conditions (pH 3.5-4.5) without apparent loss of activity. Some 
research groups have also used native protein A, or different engineered versions of it, 
with quantum dot
2
 and magnetic nanoparticles
3, 4
 for protein detection or labeling. 
However, none have taken advantage of DNA nanotechnology to enhance the 
capabilities and possibilities of using EZZ protein as a universal adapter for IgG 
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antibody-based detection and IgG antibody delivery systems. This chapter introduces 
how to conjugate the DNA-EZZ protein hybrid molecule. Later chapters will describe 
the applications of the DNA-protein hybrid molecules. 
 
Table 2.1. Binding affinity of Protein A to antibodies. 
 Strong binding Weak binding No binding 
Species Antibody Class Antibody Class Antibody Class 
Human Total IgG 
IgG1 
IgG2 
IgG4 
IgG3 
IgM 
IgA 
Fab 
ScFv 
IgD 
Mouse Total IgG 
IgG2a 
IgG2b 
IgG3 
IgG1 IgM 
Rat IgG2c Total IgG 
IgG1 
IgG2a 
IgG2b 
Cow IgG2 Total IgG 
IgG1 
n/a 
Goat IgG2 Total IgG 
IgG1 
n/a 
Sheep IgG2 Total IgG 
IgG1 
n/a 
Rabbit Total IgG n/a n/a 
Guinea Pig Total IgG n/a n/a 
Pig Total IgG n/a n/a 
Dog Total IgG n/a n/a 
Cat Total IgG n/a n/a 
Horse n/a Total IgG 
IgG(ab) 
IgG(c) 
IgG(T) 
Chicken n/a n/a Total IgY 
n/a: not available. [Source: Thermo Scientific Tech Tip #34]  
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One of the primary motivations for creating DNA-protein conjugates is to 
build artificial proteins out of different domains using DNA linkers instead of protein 
engineering. To achieve this, it is necessary to find a general method which can 
directly link DNA to the proteins of interest (POI) with an ability to control the 
stoichiometry and geometry of the proteins by DNA. As the first step, one protein 
must be able to be connected to one DNA molecule easily and efficiently.  
SNAP tag was first developed and widely used for directly labeling proteins in 
vivo with small molecules or fluorophores for imaging.
5-9
 
10
Later, it was also used to 
immobilize proteins on microarrays
11-14
 and to form DNA-protein conjugates
5, 11, 15-17
. 
SNAP protein is a mutant of the DNA repair protein O
6
-alkylguanine-DNA 
alkyltransferase (hAGT), which can react with O6-benzylguanine (BG) substrates to 
form a stable covalent thioether bond
5
. The catalytic activity of the SNAP protein is 
due to the active site residue Cys-145 which is activated through a charge relay 
involving His-146, Glu-172 and a Zn
2+
 ion.
18, 19
 However, SNAP protein does not act 
as a true enzyme since it does not have catalytic turnover activity. Thus, one SNAP 
protein will catalyze one BG group to form a 1:1 ratio product. In order to generate 
DNA-protein conjugate using SNAP tag, the EZZ protein as the POI was cloned to C-
terminal of SNAP protein. As described in Figure 2.1, BG-modified DNA as the 
substrate for SNAP protein, has to be obtained by maleimide-thiol reaction between 
BG and DNA molecules before it can be catalyzed by SNAP-EZZ protein to form 
EZZ-SNAP-DNA (ESD) conjugates.  
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Figure 2.1. Scheme of forming DNA-SNAP-EZZ protein conjugate. Thiol-modified 
DNA reacted with BG-maleimide substrate to generate BG-modified DNA, which was 
catalyzed by SNAP protein in order to form SNAP-EZZ-DNA conjugate. 
 
 
Although SNAP tag or other self-labeling protein-based methods such as the 
CLIP tag or the HaloTag are good and efficient methods, the large size of the SNAP 
protein (20 kDa) might interfere with the structure and function of the resulting 
hybrid. Therefore, we look for a general method that can directly link DNA to the POI 
without a bulky protein tag. As an attempt to achieve direct linkage, the hetero-
bifunctional crosslinker sulfo-SMCC (Thermo Scientific, Bradfold, IL) was used to 
conjugate EZZ protein with DNA. Sulfo-SMCC contains NHS ester and maleimide 
50 
 
chemical groups which specifically react with amine and sulfhydryl groups that can be 
easily modified on DNA and proteins, respectively. As described in Figure 2.2, sulfo-
SMCC reacted with amine-modified DNA to generate maleimide-activated DNA 
which easily formed a covalent link with the thiol groups from the cysteine amino 
acids of the protein. Normally, the thiol-maleimide reaction between protein and DNA 
could generate multiple DNA molecules per each protein depending on how many 
cysteine amino acids are present in the protein. However, the EZZ protein is a small 
protein which has no cysteine amino acids in its structure; therefore, it is the perfect 
candidate for taking advantage of this thiol reaction after adding a single cysteine 
residue at the C-terminus of the protein sequence. 
 
 
Figure 2.2. Scheme of forming EZZcys-DNA conjugate. Amine-modified DNA 
reacted with sulfo-SMCC to create maleimide-activated DNA product, which can 
easily react with thiol group from cysteine residue at C-terminal of EZZcys protein 
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This thiol coupling approach can be used to achieve direct linkage, but its 
generality is limited because it is rare to have a POI without any cysteine residues in 
its sequence. As a more broadly applicable method, Staphylococcus aureus Sortase 
Transpeptidase SrtA has been used. Several reviews detail the mechanisms of SrtA
20-
23
. Basically, as shown in Figure 2.3, SrtA recognizes a specific LPXTG motif, where 
X could be any amino acid, and catalyzes a cleavage between threonine (T) and 
glycine (G) to form a thiolester acyl-enzyme target intermediate. The intermediate is 
then attacked by an amine group of the oligoglycine-modified probe to form a 
transpeptidation product between target protein and probe.
23
 The amine group of 
glycine amino acid, as the nucleophile, donates an electron pair to form a chemical 
bond and plays an important role in the reaction. In fact, when an amine-modified 
oliugonucleotide is used, the yield of forming the DNA-protein conjugates by sortase 
is extremely low (data not shown). Moreover, the efficiency of the transpeptidation 
reaction also depends on the length of the oligoglycine, which is normally best 
between three and five glycines.
24
 Since polyglycine is important for sortase reactions, 
in order to obtain a protein-DNA conjugate using this method, I first conjugated a 
pentaglycine (pG) peptide with DNA before it was used to react with the target 
protein, LPETG-tagged GFP. Figure 2.4 describes the strategy of forming GFP-DNA 
conjugate catalyzed by sortase A. First, sulfo SMCC was used to crosslink amine-
modified DNA with the thiol group from the cysteine amino acid at the C-terminal of 
pG peptide. The amine group from pG-DNA conjugate then served as the nucleophile 
to attack the GFP-sortase intermediate to form a GFP-DNA conjugate.  
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Figure 2.3. Sortase-mediated transpeptidation mechanism.
23
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Figure 2.4. Scheme of forming GFP-DNA conjugate using sortase A. Step 1. 
Polyglycine (pG)-DNA conjugate was created by using sulfo-SCMM to crosslink thiol 
and amine groups between peptide and DNA, respectively. Step 2. Sortase reaction 
was performed to generate GFP-DNA conjugate.  
 
 
 
 
Step 1 
Step 2 
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2.2. Materials and methods 
2.2.1. DNA and protein materials 
All oligonucleotides (Table 2.2) were commercially synthesized with standard 
desalting by Integrated DNA Technologies (Coralville, Iowa). Without further 
purification, the oligonucleotides were dissolved in 1x TE buffer (10 mM Tris, 
pH=8.0, 1 mM ethylenediaminetetraacetic acid (EDTA)) with a final concentration of 
100 µM.  
Table 2.2. Summary of DNA materials 
DNA  5’- modification Sequence (from 5’ to 3’) 
Linker 1 Thiol-modified /5ThiolMC6/ TAC GTC AAC GTC GTC GAA TG 
Linker 2 Amine-modified /5AmMC6/ CGA GCT GCC ACA ACT CCA TC  
Linker 3 Amine-modified /5AmMC6/ TGC CAC AAC CAC CTC CGT AA  
 
 
a. Cloning, expression and purification of SNAP-EZZ protein  
The pSNAP-EZZ vector which encodes the SNAP-EZZ protein was created by 
combining EZZ protein from pEZZ18 Protein A Gene Fusion Vector (GE Healthcare) 
with SNAP protein from pSNAP-tag®(T7) vector  (New England Biolabs, Ipswich, 
MA) at its C-terminus. In addition, a short peptide linker Gly-Gly-Gly-Ser (GGGS) 
was included to create flexibility between the SNAP and EZZ proteins, and a 
polyhistidine-tag (6xHis) was added to the C-terminus of the EZZ protein. The 
molecular weight of the SNAP-EZZ protein in this work is about 36 kDa, which is 
combined between 20 kDa and 16 kDa of SNAP and EZZ proteins, respectively. 
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BL21-AI
TM
 One Shot® Chemically Competent E. coli (Invitrogen, Carlsbad, 
CA) cells transformed with the appropriate plasmid were grown overnight on LB 
(Luria Broth) plates containing 50mg/ml Ampicillin. Several colonies were selected to 
test the protein expression, and the best one was used for a 400 ml culture of bacteria 
in LB medium with 50mg/ml Ampicillin. The cells were grown at 37 °C until the 
OD600 reached approximately 0.7. Protein expression was induced by the addition of 
Arabinose to a final concentration of 20% (v/v). The cells were harvested by 
centrifugation after additional 6 hours with shaking. The cell pellet was resuspended 
and lysed in 1x BugBuster® Protein Extraction Reagent (Novagen, Madison, WI) 
(1:10 v/v). Cell debris was removed by centrifugation and the soluble part of the lysate 
was transferred into Poly-Prep
®
 Chromatography Columns (Bio-Rad, Hercules, CA) 
which contained IgG Sepharose 6 Fast Flow (GE Healthcare, Pittsburgh, PA) 
according to the manufacturer’s instructions to purify the SNAP-EZZ protein. The 
eluted protein was immediately dialyzed three times (two of two hours, and one 
overnight dialysis) in 10 mM PBS, pH=7.4, using a 3000 MWCO Slide-A-Lyzer 
® 
Dialysis Cassette (Thermo Scientific, Bradfold, IL). The concentration of SNAP-EZZ 
protein was determined by the Micro BCA
TM
 Protein Assay Kit (Thermo Scientific, 
Bradfold, IL) calibrated with bovin serum albumin (BSA) as reference protein. The 
protein was aliquoted into 1 ml of 150 µM tubes, which were then lyophilized and 
stored at -80˚C, and dissolved in de-ionized water prior to use. 
b. Cloning, expression and purification of EZZcys protein 
The EZZcys protein was created simply by adding a cysteine amino acid at the 
end of the C-terminus of EZZ protein, and cloned into a pET 18b(+) vector. Please 
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note that there is no 6xHis tag in this protein. The molecular weight of the EZZcys 
protein in this work is 16 kDa. The procedure for the expression and purification of 
EZZcys protein was similar to what was described above for the SNAP-EZZ protein. 
However, BL21-DE3 cells (Invitrogen, Carlsbag, CA) were used to transform the pET 
18b(+) vector containing EZZcys protein instead of BL21-Ai, and the cells were 
cultured in LB medium with 50 mg/ml Kanamycin instead of Ampicillin. Also, 
isopropyl thioglucoside (IPTG) was added to a final concentration of 1 mM to induce 
the expression of EZZcys protein instead of Arabinose.  
c. Expressions and purifications of LPETG-tagged GFP and Sortase A  
Plasmids encoding for GFP and Sortase A proteins were received from other 
labs. Plasmid pHTT27 (Ton-That et al. Journal of Biological Chemistry 277 (2002) 
7447-7452) encodes for hexahistidine-tagged recombinant Sortase A.  Plasmid 
pLLC152 encodes for eGFP-LPETGG-HHHHHH (Chan et al. PLoS ONE 2 (2007) 
e1164).  The incorporation of an additional glycine group following the LPXTG motif 
was shown to maximize the activity of sortase ligation (Pritz et al. J. Org Chem 72 
(2007) 3909-3912; Tanaka et al.  ChemBioChem 9 (2008) 802-807).  The molecular 
weights of the sortase and GFP proteins used in this work are 22 and 29 kDa 
respectively. 
BL21-DE3 cells transformed with the appropriate plasmid were grown 
overnight on LB plates containing ampicillin.  A single colony from each plate was 
used to inoculate a small starter culture that was then used to inoculate 2 L of a 
nutrient-rich media which was grown at 37 °C until the OD600 reached approximately 
0.7. Protein expression was induced by the addition of isopropyl thioglucoside (IPTG) 
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to a final concentration of 1 mM.  After an additional 3 hours of shaking, the resulting 
bacterial mass was harvested and lysed.  The cellular lysate was purified with a 
gravity-chromatography column containing Ni-NTA resin (Qiagen) according to the 
manufacturer’s instructions.  The column eluents were collected in 1 mL fractions and 
the most highly concentrated fractions were pooled.  An overnight dialysis step was 
performed to remove low molecular weight compounds that were used to elute the 
protein from the column using a 3.5 kDa molecular weight cut-off Spectra/Por 
membrane (Spectrum Laboratories) and dialysis buffer (71 mM Tris-HCl pH 8.0, 214 
mM NaCl).  Glycerol was added to the dialysate product to a final concentration of 
30% by volume and the resulting solution was divided into small aliquots that were 
stored at −20 °C.  The purity and concentration of the final protein product was 
assessed by SDS-PAGE analysis and Bradford assay respectively. 
2.2.2. Synthesis of EZZ-SNAP-DNA (ESD) conjugates by SNAP-tag 
Thiol-modified DNA linker 1 (IDTDNA, Coralville, Iowa) (Table 2.2) was 
first reduced by tris(2-carboxyethyl)phosphine (TCEP) (Sigma, Ronkonkoma, NY) at 
1:100 molar ratio at 25
o
C for an hour. After the excess of TCEP was removed by 
Microcon Centrifugal Filter Devices YM-3 (Millipore Corp., Billerica, MA), thiol-
modified DNA was reacted with BG-maleimide (New England Biolabs, Ipswich, MA) 
at 1:5 molar ratio in 10 mM Tris buffer, pH= 7.5 at 30
o
C, overnight to form BG-
modified DNA. The excess of BG-maleimide was removed again by using Microcon 
Centrifugal Filter Devices YM-3 (Millipore Corp., Billerica, MA) before BG-modified 
DNA was reacted with 50 µM of SNAP-EZZ protein at 5:1 molar ratio between DNA 
and protein. The reaction was incubated at room temperature, shaken at 900 rpm, 
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overnight, and the EZZ-SNAP-DNA product was confirmed by SDS-PAGE gel 
electrophoresis under denaturing conditions, and then purified by a Sephacryl S-200 
HR gel filtration column at flow rate of 0.15 ml/min. 
2.2.3. Synthesis of EZZcys-DNA conjugates by sulfo-SMCC  
The scheme for the synthesis of EZZcys-DNA conjugate is shown in Figure 8. 
First, maleimide-activated DNA was prepared by using amine-modified DNA linker 3 
(Table 2.2) with 10 mM sulfo-SMCC in 1x PBS buffer, pH 7.4 at 1:40 molar ratio at 
room temperature for 2 hours. The excess sulfo-SMCC was removed by Microcon 
centrifugal filter devices YM-3 (Millipore Corporation, Billerica, MA) with 2 times of 
washing with 400 µl of 1x PBS buffer, pH 7.4 following the company’s instruction. 
The DNA solution was then run through Illustra Micro Spin G-25 columns (GE 
Healthcare, Pittsburgh, PA) to completely remove any trace of sulfo-SMCC left in the 
solution. It is important to completely remove sulfo-SMCC since it would otherwise 
reduce the yield of the reaction between maleimide and thiol groups (data not shown). 
The maleimide-modified DNA should be used to react with thiol-modified protein 
immediately, but can be stored at 4
o
C for about two days to avoid losing the reaction 
specificity for sulfhydryl group by hydrolysis.  
Second, EZZcys protein was reduced with tris(2-carboxyethyl)phosphine 
(TCEP) (Sigma, Ronkonkoma, NY) to break down the protein dimers formed by the 
cysteine-cysteine disulfide bond to give the active thiol group which reacts with 
maleimide group from DNA.  EZZcys protein dissolved in 1x PBS buffer, pH 7.4 was 
mixed with TCEP at 1:100 molar ratios, and incubated at room temperature for 15 
minutes. Free TCEP was removed from the protein by using Microcon centrifugal 
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filter devices YM-10 (Millipore Corporation, Billerica, MA) following the company’s 
instruction and washed four times with 1x PBS buffer, pH. 7.4. The reduced EZZcys 
protein was reacted with maleimide-modified DNA immediately to avoid the reform 
of the protein dimers.  
50 µM of EZZcys protein was mixed with maleimide-modified DNA at a 1:10 
molar ratio, and shaken at 900 rpm, at room temperature for overnight.  The product 
was confirmed by 4-20% SDS-PAGE gel electrophoresis under denaturing conditions, 
and purified by Sephacryl S-200 HR gel filtration column at flow rate of 0.15 ml/min. 
2.2.4. Synthesis of GFP-DNA conjugates by Sortase A enzyme  
The synthesis of DNA-GFP protein conjugate was performed in two steps. The 
first step involved the synthesis of polyglycine (pG)-DNA peptide conjugate to act as 
the amine nucleophile in the sortase reaction later. The second step is the sortase 
reaction between GFP and pG-DNA to form DNA-GFP protein conjugate.  
a. Synthesis of polyglycine-DNA (pG-DNA) conjugate by sulfo-SMCC  
Maleimide-activated DNA was first prepared by using amine-modified DNA 
linker 2 (Table 2.2) as described in the synthesis of EZZcys-DNA conjugate by sulfo-
SMCC above. It was then reacted with polyglycine (pG) peptide 
(GGGGGHHHHHHC, MW=1.2 kDa) at 1:1 molar ratio at 4°C for overnight to form 
polyglycine-DNA (pG-DNA) conjugate after boiling at 95°C for 15 minutes 
immediately before the reaction. The pG-DNA product was confirmed by 3% agarose 
gel electrophoresis in 1x TAE buffer (40 mM Tris-acetate and 1 mM EDTA with a pH 
of 8.3), and purified by Bio-gel P30 gel filtration (Bio-Rad, Hercules, CA) to eliminate 
unreacted peptides, followed by purification using Ni-NTA (Qiagen, Valencia, CA) 
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columns to eliminate unreacted DNA. 
b. Synthesis of GFP-DNA conjugates by Sortase A enzyme 
5 µM of GFP protein and 5 µM of pG-DNA conjugates were added into a 
reaction buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, and 5 mM CaCl2) with 15 
µM SrtA, and incubated at 37°C for overnight. The GFP-DNA product was confirmed 
by 4-20% SDS-PAGE gel electrophoresis under denaturing conditions.  
 
2.3. Results 
2.3.1. EZZ-SNAP-DNA (ESD) conjugates 
ESD conjugates were synthesized by the catalysis of SNAP-EZZ protein to 
BG-modified DNA at 1:5 molar ratios between protein and DNA. The product was 
confirmed by 4-20% SDS-PAGE gel under denaturing conditions. The samples were 
added with SDS loading dye and heated at 95°C for 5 minutes and cooled down to 
room temperature before loading. The gel was run in Tris-Glycine SDS running 
buffer, at 250 volts, at room temperature for 30 minutes. The gel was first stained with 
GelRed dye, which specifically stained DNA products for about one hour. After 
imaging by UV exposure with Kodak Imaging Station 4000R, the gel was stained for a 
second time with Coomassie Brilliant Blue (CBB) R-250 staining solution for 10 
minutes then de-stained overnight to visualize protein products. Figure 2.5 shows that 
ESD conjugates in lane 1 with higher molecular weight migrated slower than BG-
modified DNA only in lane 2 and SNAP-EZZ protein only in lane 3.  
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Figure 2.5. Confirmation of EZZ-SNAP-DNA (ESD) conjugates on 4-20% SDS-
PAGE gel electrophoresis. The same gel was first stained with GelRed to visualize 
DNA products (a) and then stained with Coomassie Brilliant Blue (b) to visualize 
protein products. 1. ESD conjugates. 2. DNA only. 3. EZZ-SNAP protein only.   
 
 
Furthermore, it was noticed that the mobility of DNA-SNAP-EZZ conjugates 
varied depending on the running conditions of PAGE gel electrophoresis. When run 
on SDS-PAGE gel electrophoresis under denaturing condition, ESD conjugates 
migrated slower than the individual components as shown in figures 2.5 and 2.6a. On 
the other hand, when run on native PAGE gel electrophoresis under non-denaturing 
conditions while there was no SDS in the gel and running buffer, DNA-SNAP-EZZ 
conjugates migrated faster than SNAP-EZZ protein itself (Figure 2.6b). This 
unexpected behavior could be due to the effects of charge and mass of the DNA-
protein conjugate. In the SDS-PAGE case, since SDS is highly negatively- charged, it 
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cancels out the charge effects of the protein and DNA, which is also negatively 
charged. Thus, the mobility of DNA-SNAP-EZZ conjugate and SNAP-EZZ protein 
was purely dependent on the size of the molecule, and since the DNA-SNAP-EZZ 
conjugate was bigger, it ran slower, and remained closer to the wells of the gel. On the 
other hand, in native PAGE gel electrophoresis, there was no SDS involved, so the 
total net charge effect could play a more important role than the size effect in the 
mobility of DNA-SNAP-EZZ conjugate, compared to that of SNAP-EZZ protein only.   
 
 
 
 
Figure 2.6. Mobility of EZZ-SNAP-DNA conjugates on 4-20% SDS-PAGE (A) and 
15% native PAGE (B) gel electrophoresis. The gels were stained with CBB dye. Lanes 
1. SNAP-EZZ protein only. Lanes 2. EZZ-SNAP-DNA conjugates.  
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2.3.2. EZZcys-DNA conjugates 
EZZcys-DNA conjugates were synthesized by the reaction between thiol-
modified EZZcys protein with maleimide-modified DNA at 1:10 molar ratios between 
protein and DNA. The product was confirmed by 4-20% SDS-PAGE gel under 
denaturing conditions. The samples were added with SDS loading dye and heated at 
95°C for 5 minutes and cooled down to room temperature before loading. The gel was 
run in Tris-Glycine SDS running buffer, at 250 volts, at room temperature for 30 
minutes. The gel was stained with Coomassie Brilliant Blue (CBB) R-250 staining 
solution for 10 minutes and de-stained overnight. Figure 2.7 shows that EZZcys-DNA 
conjugates in lane 2 with higher molecular weight migrated slower than the EZZcys 
protein only in lane 1. 
 
 
 Figure 2.7. Confirmation of EZZcys-DNA conjugates on 4-20% SDS-PAGE gel 
electrophoresis. 1. EZZcys protein only. 2. EZZcys-DNA conjugates. 
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2.3.3. GFP-DNA conjugates 
Glycine-modified DNA (pG-DNA) conjugates were needed to serve as an 
amine nucleophile in sortase reactions for GFP-DNA conjugation. pG-DNA 
conjugates were obtained by a thiol-to-maleimide coupling reaction between thiol-
modified polyglycine (pG) peptide and maleimide-modified DNA. The product was 
confirmed with 3% agarose gel electrophoresis in 1x TAE buffer (40 mM Tris-acetate 
and 1 mM EDTA with a pH of 8.3) at 120 volts for 50 minutes (Figure 2.8). The gel 
was stained with GelRed dye and imaged with the Kodak Imaging Station 4000R.  
After pG-DNA was formed, it was reacted with LPETG-tagged GFP protein 
and sortase A enzyme. SrtA enzymes recognized the LPETG sequence on GFP protein 
and cleave it between T and G position to form an immediate GFP-sortase through a 
thiolester bond. The amine group at N-terminal of pG-DNA then acted as a 
nucleophile to attack the GFP-sortase intermediates and replace the thiolester bond 
with a peptide bond to form the GFP-DNA final products. First, different components 
were mixed to confirm that the final products were formed through SrtA enzymatic 
catalysis. In addition, the literature gives conflicting conditions for performing sortase 
reactions. Some reports have used very high concentrations of sortase (50 µM) [cite] 
while others recommended very low concentrations (50 nM – 1 µM) [cite]. Therefore, 
different molar ratios between enzymes, proteins and DNA were investigated to define 
the best reaction condition (Table 2.3) in this particular case. Figure 2.9 showed the 
results of forming GFP-DNA conjugates using the catalysis of the SrtA enzyme. SrtA, 
GFP and DNA were represented by “S”, “G”, and “D”, respectively. As expected, 
higher concentrations of SrtA enzymes gave higher yields. On the contrary, higher 
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concentrations of pG-DNA did not improve the coupling efficiency at all, in contrast 
to most of the literature, which recommends using three to five times more DNA than 
proteins. Unfortunately, due to the limit of pG-DNA amount available, I could not 
investigate the effects of using much higher excess of DNA vs. protein amounts, for 
example, five to ten fold excess. However, with the GSD4 condition (Table 2.3) which 
utilized 1:3:1 molar ratio between GFP:SrtA:DNA, the yield of GFP-DNA was 
obtained at about 50% yield based on protein, which is as high as literatures reported. 
Normally, the yield of sortase reactions between proteins and proteins or protein and 
small molecules would be higher (about 80%). However, DNA is much larger than 
small molecules, and highly negatively charged which might cause an internal ionic 
reaction between peptide backbone and phosphate backbone of DNA. Thus, this 
reduced the availability of the amine group of glycine for the ligation. After 
comparing the conditions in Table 2.3, I decided to choose the GSD4 condition as the 
standard for making GFP-DNA conjugates.  
 
 
Figure 2.8. Confirmation of pG-DNA conjugates. 1. 140 pmol of peptide-DNA after 
Ni-NTA beads purification. 2-5. 40, 80, 160, and 240 pmol of DNA, respectively. 
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Table 2.3: Summary of sortase reaction conditions 
Samples S D G GS DS GD GSD1 GSD2 GSD3 GSD4 
GFP (µM)   5 5  5 5 5 5 5 
Sortase (µM) 5   5 5  1.7 5 5 15 
pG-DNA (µM)  5   5 5 5 15 5 5 
molar ratios 1 1 1 1:1 1:1 1:1 1:1/3:1 1:1:3 1:1:1 1:3:1 
 
 
 
Figure 2.9.  Synthesis of GFP-DNA conjugates using SrtA. All samples were boiled at 
95°C for 5 minutes in SDS loading buffer before running 4-20% SDS-PAGE gel 
electrophoresis at 250 volts for 30 minutes. S. Sortase only. G. GFP only. D. pG-DNA 
only. GS. GFP + Srt A. DS. DNA + Srt A. GD. GFP + pG-DNA. GSD. GFP + Srt A + 
pG-DNA at different molar ratios. GFP-DNA conjugates with larger molecular 
weights would migrate slower on SDS-PAGE gel, compared to individual 
components. Higher concentrations of SrtA gave better yields of forming GFP-DNA 
conjugates while higher concentrations of pG-DNA did not substantially improve the 
yield.  
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2.4. Conclusions 
 In conclusion, three methods (utilizing the SNAP tag, sulfo-SMCC, and 
sortase A enzyme) were successfully used to obtain monovalent protein-DNA hybrid 
materials. The efficiency of conjugation was high, about 50% in the case of sortase, up 
to 80-90% in the case of SNAP tag and sulfo-SMCC. However, there are still many 
disadvantages for each method. For example, the SNAP tag method introduces a large 
tag (20kDa protein) beside the target proteins. Sulfo-SMCC only works for 1:1 
conjugation when the target proteins do not contain cysteine amino acid in the 
sequences, which is very rare. Sortase A requires an additional conjugation step of pG-
DNA products which is relatively low yield by now and requires further optimization. 
In addition, all of the described methods required multiple steps of modifications and 
purification of both proteins and DNA. 
Unlike multivalent protein-DNA conjugation methods, which are more 
straightforward and involve fewer steps, monovalent conjugation methods face many 
challenges. The most significant disadvantage for all monovalent protein-DNA 
conjugation methods is probably the requirement for pre-modifications of the proteins 
and DNA. Proteins have to be re-cloned to add functional groups or tags, which is not 
always convenient or possible. DNA also needs to be modified with suitable 
functional groups to be able to react with proteins. Therefore, finding a simple (ideally 
single step) reaction for the protein-DNA conjugation is very desirable, but still a big 
challenge for chemists and biochemists. However, despite of these disadvantages, the 
current status of protein-DNA conjugation technology is still more than sufficient for 
creating exciting new protein-DNA hybrid materials with great potential, particularly 
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for the applications in protein detection and drug delivery.  
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CHAPTER 3: CHARACTERIZATIONS OF PROTEIN-DNA CONJUGATE  
 
3.1. Introduction 
The main purpose of this chapter is to confirm that the protein and DNA are 
still functional after their conjugation. To confirm the DNA function, the DNA linker 
of the ESD conjugate was hybridized with its complementary sequence of the DNA 
nanobarcodes to form EZZ-SNAP-DNA (ESD) nanobarcodes. As discussed in the 
introduction chapter, DNA nanobarcodes have been developed in the previously-
published works in our lab 
1
 and successfully used to detect DNA targets with a 
detection limit at 620 attomole. The barcodes were built based on the ratios of two 
fluorescent dyes, red and green colors which corresponds to Alexa 546 (Ex= 556 nm 
and Em= 573 nm) and Alexa 488 (Ex= 495 nm and Em= 519 nm) dyes, respectively, 
but is independent of the labeled positions. Therefore, the biggest advantage of this 
system is that it only requires green and red excitation and filter channels to resolve 
the differences between the DNA nanobarcodes. Theoretically, the coding capacity 
(C) of DL-DNA structures was determined by the number of colors (L) and the 
number of labeled positions (P) and was calculated by the formula, C=(P+L-1)!/P!(L-
1)!. However, in this particular case when using only two (red and green), 
C=(P+1)!/P!. As a demonstration for multiplexed detection of proteins using DNA 
nanobarcodes in the next chapter, I only used the simplest barcode system which was 
built from just Y-shaped DNA and gave 3 different color ratios: R2G0, R0G2, and 
R1G1. Here, “R” represents the red dye, and “G” represents the green dye, and the 
number corresponds to the number of red and green dyes used in the nanobarcodes.  
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In addition, two methods were used to confirm the binding of EZZ protein to 
IgG antibodies. The first method was based on Streptavidin-coated polystyrene beads, 
and the fluorescence signal was detected from a fluorescence microscope. This bead-
based format was also considered for its potential detection applications using ELISA, 
microarrays, or flow cytometer-based approaches. The second method was conducted 
on PVDF membrane as a dot blotting technique. This membrane-based format could 
potentially be used for 1D or 2D western blotting applications for the detection of 
proteins as well. Unfortunately, there were not enough signal generated from the 
conventional dot blotting method, using a blotting device such as the Bio-Dot 
Microfiltration Apparatus (BioRad, Hercules, CA), to be detected from a digital 
camera under UV exposure, unless a large amount of IgG antibodies and ESD 
nanobarcodes were used (at least 100 pmol). Therefore, in order to amplify the 
fluorescent signal and use a much lower volume (0.5-1 µl) and amount (0.5-1 pmol) of 
target, I designed a miniaturized, fast, and simple dot blot method which also reduced 
the time required for the blotting procedure to 5-10 minutes rather than three hours as 
in the conventional approach. 
The combination of DNA nanobarcodes and different IgG binding generated a 
library of IgG nanobarcodes which were suitable for multiplexed protein detection. 
However, would the new configuration of IgG nanobarcodes affect the binding ability 
and efficiency of IgG antibodies due to steric hindrance of the ESD nanobarcodes? To 
answer that question, the IgG antibody competitive assay was conducted to prove that 
binding to ESD nanobarcodes did not affect the binding efficiency of IgG antibodies.  
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3.2. Materials and methods 
3.2.1. DNA nanobarcodes formation 
All oligonucleotides were commercially synthesized by Integrated DNA 
Technologies (Coralville, Iowa). Only fluorescent-labeled sequences were HPLC 
purified, and the rest were purified by standard desalting. Sequences from Table 3.1 
were derived from previously published works.1Without further purification, the 
oligonucleotides were dissolved in TE buffer (10 mM Tris, pH=8.0, 1 mM 
ethylenediaminetetraacetic acid (EDTA)) with a final concentration of 100 µM. Y-
DNA was synthesized by mixing the three oligonucleotide components Ya, Y b, and Yc 
at a molar ratio of 1:1:1 in annealing buffer (10 mM Tris, pH 8.0, 1 mM EDTA, and 
50 mM NaCl) with a final concentration of 10 µM for each oligonucleotide. The 
number of Ya or Yb with “R” and “G” defined the color ratios of the DNA 
nanobarcodes.  For examples, R1G1-DNA nanobarcode could be formed with YaR, 
YbG, and Yc_antilinker 1, or with YaG, YbR, and Yc_antilinker 1; both would give the 
same outcome. The R2G0-DNA nanobarcode was formed with both YaR and YbR, and 
Yc_antilinker 1, and similarly, the R0G2 -DNA nanobarcode was formed with both 
YaG and YbG, and Yc_antilinker 1. The hybridization was performed with the 
annealing program shown in Table 3.2 using a thermo-cycler from Eppendorf AG 
(Hamburg, Germany).  
3.2.2. DNA hybridization confirmation (ESD nanobarcodes formation) 
The formation of ESD nanobarcodes was very simple, requiring only a single 
step of simple mixing. EZZ-SNAP-DNA (ESD) conjugate was mixed with R2G1-, 
R0G2-, R1G1-DNA nanobarcodes at a 1:1 molar ratio at room temperature for an hour 
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to form R2G0-, R0G2-, and R1G1-labeled ESD nanobarocodes. The products were 
confirmed with a 4-20% native PAGE gel, and purified by a Sephacryl S-200 HR gel 
filtration column at flow rate of 0.15 ml/min. 
Table 3.1: Sequences of oligonucleotides for fluorescent-labeled Y-DNA 
Name  Modification Sequences (from 5’ to 3’) 
YaR 5’-Alexa 546 TGGATCCGCATGACATTCGCCGTAAG 
YbR 5’-Alexa 546 CTTACGGCGAATGACCGAATCAGCCT 
YaG 5’-Alexa 488 TGGATCCGCATGACATTCGCCGTAAG 
YbG 5’-Alexa 488 CTTACGGCGAATGACCGAATCAGCCT 
Yc_anti 
linker 1  
None AGGCTGATTCGGTTCATGCGGATCCACATT
CGACGACGTTGACGTA 
 
Table 3.2: Annealing program for Y-DNA formation 
Control Block 
  Lid=105
o
C 
  
Wait Auto 
 Step 1: 95
o
C
 
5 minutes 
 Step 2: 75
o
C
 
2 minutes 
Step 3: 60
o
C
 
2 minutes 
 Step 4:  60
 o
C
 
30 seconds 
  Temperature -0.5
 o
C
 
 Step 5:  go to step 4 repeat 80 times 
 Step 6:  Hold  4
0C
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3.2.3. IgG binding confirmation  
a. Bead-based confirmation 
The IgG antibodies were biotinylated using the EZ-Link Sulfo-NHS-Biotin and 
Biotinylation Kits (Thermo Scientific, Rockford, IL) before immobilization onto 10 
µm-size Streptavidin polystyrene beads (Bangs Laboratories, Inc., Fishers, IN). The 
IgG-immobilized beads were washed with 1x PBS, pH 7.4 three times before adding 
ESD nanobarcodes to 400 nM final concentration. The beads were gently rotated at 
room temperature for two hours, and washed with 1x PBS, pH 7.4 three times again 
before taking the images with the Olympus BX61 fluorescence microscope.  
b. Membrane-based confirmation  
The Low Fluorescence PVDF Transfer Membrane (Thermo Scientific, 
Rockford, IL) was cut approximately to 0.5 inch x 2.0 inch in size. Each dot was wet 
with 10 µl of methanol before spotting with 0.5 µl of 60 fmol of IgG antibody, using 
10 µl round gel tips (USA Scientific, Ocala, FL) to obtain 250 µm diameter dots. The 
membrane was wet with 200 µl of methanol again before blocking with 500 µl of 5% 
skim milk in TBST blocking buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, and 
0.005% Tween 20) in a 5ml clear glass dram vial for 5 minutes. ESD nanobarcodes 
were added into the samples to 50 nM final concentration. The membrane was 
incubated at room temperature for 4-6 hours before washing with TBST blocking 
buffer 3 times, and imaged with an Olympus BX61 fluorescence microscope after 
drying. 
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3.2.4. IgG antibody competitive assay 
6His-tagged sortase protein was used as the antigen, and anti-His IgG antibody 
(mouse, monoclonal IgG antibody) without labeling was used as the competitor of the 
R2G0- labeled anti-His IgG nanobarcode in the assay. The samples were compared by 
looking at the fluorescence intensity of the antigen dots in dot blotting format as 
described above. The experiment was set up as follows: Three sets of samples were 
prepared, and each set of samples contained 4 dots of 1 pmol antigen and 2 dots of 1 
pmol GAPDH protein as controls. Set 1 was labeled with 2.5 pmol of normal anti-His 
IgG (no label), set 2 was labeled with 2.5 pmol of R2G0-labeled anti-His IgG (red 
label), and set 3 was labeled with 2.5 pmol of R2G0- labeled anti-His IgG and 2.5 pmol 
of anti-His IgG together. These samples were incubated at room temperature for 6 
hours before washing and imaging with an Olympus BX61 fluorescence microscope 
after drying. 
 
3.3. Results 
3.3.1. DNA nanobarcodes 
Figure 1 shows a schematic drawing of the R1G1_DNA nanobarcode, which 
contains one red dye and one green dye on two arms of the Y-DNA, while 2R0G_ and 
0R2G_Y-DNA would have two red or two green dyes on the Y-DNA, respectively. 
The third arm of the Y-DNA contains a 20-nt sticky end, which is complementary to 
the ssDNA sequence of DNA-protein conjugate. 
Fluorescent-labeled Y-DNA samples  were confirmed by 3% agarose gel 
(SeaKem® LE Agarose, Lonza, Rockland, ME) in Tris-acetate-EDTA (TEA) buffer 
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(40 mM Tris, 20 mM Acetic Acid, and 1 mM EDTA, pH 8.0, Biorad, Hercules, CA) at 
120 volts at room temperature for 50 minutes. The images were taken by a Kodak 
Imaging Station 4000R (Kodak, Rochester, NY) with red and green filters, and 
processed with ImageJ to obtain the overlay images. Figure 3.2 shows the Y-DNA 
nanobarcodes (lane 3-5) were fully formed with three strands of oligonucleotides 
compared to a partial Y-DNA with two strands (lane 2) and one strand of 
oligonucleotide (lane 1). Lane 3-4 also showed the clear distinction of colors from 
three nanobarcodes, which were comprised of two red, one red and one green, and two 
green dyes, respectively. 
 
Figure 3.1. Schematic drawing of R1G1-Y-DNA anti linker 1, which contained one red 
dye from the Ya strand, one green dye from the Yb strand, and a complimentary 
sequence to protein-DNA conjugate from the Yc strand. 
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Figure 3.2. Gel images of fluorescent-labeled DNA nanobarcodes. 1. YaG. 2. 
Partial Y with YaR and Yc. 3-5. R2G0-, R1G1-, and R0G2-DNA nanobarcodes, 
respectively.  
 
3.3.2. Protein nanobarcodes formation 
 ESD nanobarcodes were formed by mixing ESD conjugates with different Y-
DNA nanobarcodes at 1:1 molar ratio, and incubated at room temperature for about 
one hour. The products were confirmed with 4-20% native PAGE gel (Biorad, 
Hercules, CA) in 1x Tris/Glycine running buffer (25 mM Tris, 192 mM Glycine, pH 
8.3) with 250 volts at room temperature for 60 minutes. Prior to staining, the gel was 
imaged by a Kodak Imaging Station 4000R (Kodak, Rochester, NY) with both red and 
green filters to capture only fluorescent-labeled products. It was then stained with 
GelRed dye (Biotium Inc., Hayward, CA) for one hour, and imaged again with Kodak 
Imaging Station 4000R to further visualize ESD conjugates and other DNA products 
such as DNA nanobarcodes and ESD nanobarcodes. Finally, the same gel was stained 
with Coomassie Brilliant Blue (CBB) R-250 staining solution for 10 minutes and de-
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stained overnight to visualize the protein products, and the image was scanned with a 
DR-4010C Canon scanner. 
 Figure 3.3 confirms the formation of ESD nanobarcodes. Gels A, B, C 
correspond to the same gel but were imaged after staining with different dyes. Gel A 
was imaged before any staining, so only fluorescence-labeled products such as DNA 
nanobarcodes (lane 3, 4), and ESD nanobarcodes (lane 5-7) could be visualized.  Gel 
B was stained with GelRed, a DNA staining dye, so any products containing DNA 
could be visualized, including the ESD conjugate (lane 2), the DNA nanobarcodes 
(lane 3, 4) and the ESD nanobarcodes (lane 5-7). At this point, it is clear that the ESD 
nanobarcodes were formed through the hybridization of the DNA linker with the 
R2G0-DNA nanobarcode. When mixing only the SNAP-EZZ protein and DNA 
nanobarcodes in lane 4, there were no shifted products as in lane 4-7 since there was 
no DNA linker in the SNAP-EZZ protein to bind with the R2G0-DNA nanobarcode in 
the mixture.  
 
Figure 3.3. Characterization of ESD nanobarcodes on 4-20% native PAGE gel 
electrophoresis. 1. SNAP-EZZ protein. 2. ESD conjugate. 3. R2G0-DNA nanobarcode. 
4. SNAP-EZZ protein with R2G0-DNA nanobarcode. 5-7. R2G0-, R1G1-, and R0G2-
labeled ESD nanobarcodes, respectively.  
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3.3.3. IgG binding confirmation (IgG nanobarcodes detection) 
After the ESD nanobarcodes were formed, they were used to confirm the 
ability to bind to IgG antibodies of EZZ domain. If after the conjugation, the EZZ 
protein had lost its function and could no longer bind to IgG antibodies, the ESD 
nanobarcodes would be useless. Therefore, this is an important characterization step 
since protein is normally less stable than DNA physically and chemically. The 
confirmation of IgG binding of ESD nanobarcodes was carried out by both bead-based 
and dot blotting-based protocols. The IgG antibodies used in this work were mostly 
rabbit polyclonal antibodies or carefully chosen from other species to have a strong 
binding affinity to EZZ protein, according to Table 2.1. Three rabbit polyclonal IgG 
antibodies, anti-Insulin IgG, anti-Glucagon IgG, and anti-PDX-1 IgG, were confirmed 
with ESD nanobarcodes on microbeads and PVDF membrane. As negative controls, 
mouse monoclonal anti-p53 IgG antibody, isotype IgG1 antibody, and goat polyclonal 
anti-PDX-1 IgG antibody, which all have weak bindings to protein A, were used. The 
beads or dots were imaged with the Olympus BX61 fluorescence microscope with the 
same exposure time, and images were processed by ImageJ software with the same 
min-max value setting for all images. 
 Beads-based confirmation 
Figure 3.4 shows the results of ESD nanobarcodes binding to different IgG 
antibodies. Figure 3.4A illustrates the scheme of the bead-based IgG binding 
experiments. Biotinylated-IgG antibodies were immobilized onto 10 µm streptavidin 
beads, incubated with DNA nanobarcodes for 4-6 hours, washed to remove unbound 
DNA nanobarcodes, and imaged with the Olympus BX61 fluorescence microscope 
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using the 20x objective for both red and green channels. The images were processed 
with ImageJ software to obtain the overlay images. Figures 3.4B, 3.4C, and 3.4D show 
the strong binding of R2G0-, R1G1-, and R0G2-ESD nanobarcodes to rabbit polyclonal 
anti-glucagon, anti-PDX-1, and anti-insulin IgG antibodies, respectively. Mouse, 
monoclonal anti-p53 IgG antibody, subtype IgG1a have weak binding affinity to 
protein A; therefore, there was almost no fluorescence signal on the beads of figure 
3.4E, compared to those of figure 3.4C which have the same R1G1-ESD nanobarcodes 
used. This result shows that EZZ protein from ESD nanobarcodes was fully 
functional, and was able to bind to IgG antibodies strongly and specifically. 
 
Figure 3.4. IgG nanobarcodes confirmation by beads. (A) Scheme illustrating 
microbead ratiometric color labeling. Beads were tagged with IgG antibodies then 
labeled with ESD nanobarcodes. (B) Anti-glucagon IgG was labeled with R2G0-ESD 
nanobarcode. (C) Anti-PDX-1 IgG was labeled with R1G1-ESD nanobarcode. (D) 
Anti-insulin IgG was labeled with R0G2-ESD nanobarcode. (E) Anti-p53 IgG1, which 
has weak binding to EZZ protein, was labeled with R1G1-ESD nanobarcodes as a 
negative control. The insets show magnified views of the beads.  
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 Membrane-based (dot blotting) confirmation 
The IgG binding ability of ESD nanobarcodes was also confirmed using a dot 
blotting format. This also served to confirm that the fluorescence signals could be 
detected on PVDF membrane for protein detection applications later. Dots containing 
60 fmol of different IgG antibodies were spotted onto a PVDF membrane, and 
incubated with different ESD nanobarcodes separately at 50 nM final concentration as 
described in scheme A of Figure 3.5. Figures 3.5B, 3.5C, and 3.5D are the images of 
dots showing the strong binding of anti-glucagon IgG labeled with R2G0-ESD 
nanobarcodes, anti-PDX-1 IgG labeled with R1G1-ESD nanobarcodes, and anti-insulin 
IgG labeled with R0G2-ESD nanobarcodes, respectively. Figure 3.5E and 3.5F are 
negative control samples of the weak binding between goat polyclonal anti-PDX-1 
IgG with R0G2-ESD nanobarcode, and mouse monoclonal anti-p53 IgG, subtype 
IgG1a with R2G0-ESD nanobarcodes, respectively. 
 
3.3.4. IgG antibody competitive assay 
To further investigate the binding affinity of IgG nanobarcodes, an antibody 
competitive assay was conducted to check whether the binding efficiency of IgG 
antibodies were reduced or inhibited by the steric hindrance effects of ESD 
nanobarcodes or not. One pmol of His-tagged sortase protein and GAPDH protein was 
deposited on PVDF membrane as the targets and negative controls, respectively. The 
target proteins were separately incubated without fluorescence labeling (Figure 3.6A), 
with fluorescence labeling (Figure 3.6B), and with both (Figure 3.6C) antibodies in 
different vials to compare the binding ability and efficiency. GAPDH proteins (Figure 
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3.6D) were included in each strip to confirm that the fluorescence signals were only 
specific to the target proteins.  
 
 
 
Figure 3.5. IgG nanobarcodes were confirmed by dot blotting. (A) Scheme illustrating 
dot blotting ratiometric color labeling. 60 fmol of IgG was dotted onto PVDF 
membrane then labeled with ESD nanobarodes. (B) Anti-glucagon IgG labeled with 
R2G0-ESD nanobarcode. (C) Anti-PDX-1 IgG labeled with R1G1-ESD nanobarcode. 
(D) Anti-insulin IgG labeled with R0G2-ESD nanobarcode. (E-F) Goat polyclonal anti-
PDX-1 IgG and mouse monoclonal anti-p53 subtype IgG1 labeled with R0G2- and 
R2G0-ESD nanobarcodes as negative controls, which have weak binding to EZZ 
protein,. The size of each dot is around 250 µm. 
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As a result, the control dots (D) and dots labeled with anti-His IgG (A) did not 
give any fluorescence signals, while the dots with fluorescence-labeled IgG antibodies 
(C and D) gave strong signals. The mean of fluorescence intensity was measured by 
ImageJ to quantify differences in the binding efficiency (Table 3.3). If binding to ESD 
nanobarcodes altered the binding ability of IgG antibodies, the fluorescence intensity 
in dot D would be less than that in dot C since R2G0-labeled IgG was competing with 
non-labeled IgG antibodies. However, the fluorescence intensity was similar in these 
cases, which indicated that IgG nanobarcodes still retained their original strong 
binding efficiency to target proteins at 10 nM concentration after the conjugation.  
 
 
Figure 3.6. IgG competitive assay to confirm the binding efficiency of ESD 
nanobarcodes to IgG antibody. (A) His-tagged proteins were labeled with anti-His IgG 
antibodies. (B) His-tagged proteins were labeled with R2G0-anti-His IgG 
nanobarcodes. (C) His-tagged proteins were labeled with both anti-His IgG and R2G0-
anti-His IgG nanobarcodes. (D) GAPDH proteins were labeled with R2G0-anti-His 
IgG nanobarcodes. 
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Table 3.3. Mean of fluorescence intensity for IgG competitive assay. 
Dot Antigen IgG labeling Mean of 
fluorescence 
intensity 
A His-tagged protein anti-His IgG antibodies 200 
B His-tagged protein R2G0-anti-His IgG nanobarcodes 2500 
C His-tagged protein Both anti-His IgG antibodies and 
R2G0-anti-His IgG nanobarcodes 
2700 
D GAPDH protein R2G0-anti-His IgG nanobarcodes 200 
 
 
3.4. Conclusions 
The ESD conjugate could be used as a universal adapter for interfacing 
between the DNA and IgG antibody worlds since it has the ability to hybridize to 
R2G0-, R1G1-, and R0G2-DNA nanobarcodes and bind to IgG antibodies to generate a 
variety of fluorescence-labeled IgG nanobarcodes. The generation of a IgG 
nanobarcodes library, through a convenient and rapid process that involves only 
simple mixing, gives us the freedom to select suitable labels for detecting multiple 
targets simultaneously.  
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Chapter 4: APPLICATION 1 - Multiplexed Protein Detection 
 
4.1.  Introduction 
As mentioned in the previous chapters, protein detection is one of the main 
applications of DNA-protein hybrid materials due to the advantages of having both 
DNA and protein moieties on one molecule. In this chapter, ESD conjugate, which 
was described in chapter 2 and 3, will serve as a universal adapter to interface between 
DNA nanobarcodes and IgG antibody to generate a IgG-based DNA nanobarcodes 
(IgG nanobarcodes) for multiplexed protein detection. In this approach, EZZ protein 
from ESD conjugate interacted with IgG antibodies as probes, and DNA nanobarcodes 
was used as the reporters, as illustrated in Figure 4.1. The IgG nanobarcodes can be 
generated through the hybridization process just by simply mixing all the components 
together at 1:1:1 molar ratio between DNA nanobarcodes, ESD conjugate, and IgG 
antibodies. This generated a library of IgG nanobarcodes suitable for multiplexed 
protein detection with the freedom of choosing the color labels rather than relying on 
the limited prelabeled primary IgG antibodies available on the market. Similar to using 
prelabeled primary antibody in protein labeling or detection, using IgG nanobarcodes 
to detect proteins requires fewer steps in staining and washing procedures, which is 
more convenient, and time efficient. Moreover, the IgG nanobarcode system can be 
used as a versatile platform for multiplexed protein detection in several different 
systems including microbead-based assay, dot-blotting, western blotting, and 
immunofluorescence. 
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Figure 4.1. Scheme illustrating the generation of IgG nanobarcodes as a versatile 
platform for protein detection. The ESD conjugate served as a universal adapter for 
interfacing with a variety of both IgG antibodies and DNA nanobarcodes to generate a 
library of fluorescence-labled IgG antibodies for multiplexed protein detection.  
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4.2. Materials and Methods 
4.2.1. Bead-based protein detection 
First, the biotinylated-anti linker 1 oligonucleotide, which was complimentary 
to the DNA linker on the ESD conjugate, was deposited on 10 µm streptavidin 
polystyrene (PS) beads at a 10:1 molar ratio between the oligonucleotide and the 
binding capacity of the beads. The beads were rotated gently at room temperature for 
30 min, and washed three times with TBST buffer (50 mM Tris-HCl, pH 7.4, 150 mM 
NaCl, and 0.005% Tween 20) after centrifuging at 1200 rcf for one minute to remove 
the free biotinylated-oligonucleotide. Second, the ESD conjugate was hybridized to 
anti linker 1-immobilized PS beads at a 1:1 molar ratio, and the beads were rotated 
gently at room temperature for one hour. Next, without washing, the anti-His IgG 
antibody was added to the ESD-modified beads at a 1:3 molar ratio between IgG 
antibody and ESD conjugate, and the beads were rotated gently at room temperature 
for overnight. The anti-His IgG-modified beads, after washing three times with TBST 
buffer, served as the capture probes for any protein targets containing a 6xHistidine 
tag.  
For pure protein detection, for example GFP and Drosophila heat shock factor 
(HSF) proteins, 3 µl of 0.2 µM anti-His beads were incubated with a 0.5 µM final 
concentration of the protein targets. The samples were rotated gently at room 
temperature for 6 hours before washing three times with TBST buffer after 
centrifuging at 1200 rcf for one minute. For protein detection from lysate, for example 
Renilla Luciferase (RL) protein, 3 µl of 0.2 µM anti-His beads was incubated with 1 
µl of 5 mg/ml lysate. The sample was rotated gently at room temperature for overnight 
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before washing five times with TBST buffer at the same conditions as above. For 
multiplexed protein detection, 3 µl of GFP, HSF, and RL beads were prepared 
separately as above and mixed together before labeling with three specific IgG 
nanobarcodes. 
After the unbound targets were washed out with TBST buffer, corresponding 
specific fluorescent-labeled IgG nanobarcodes was added to the target beads at a 400 
nM final concentration. R2G0-labeled anti GFP antibody, R0G2-labeled anti HSF 
antibody, and R1G1-labeled anti RL antibody were used to label GFP, HSF and RL 
targets, respectively. Note that with the flexibility of generating IgG nanobarcodes, we 
can use any fluorescence labels for any target by just mixing the IgG antibody with the 
desired ESD nanobarcode  color ratio. After incubation for 6 hours, the samples were 
again washed three times with TBST buffer after centrifuging at 1200 rcf for one 
minute to remove the unbound labels. The samples were concentrated to 3 µl of beads 
which was used for imaging with the Olympus BX61 fluorescence microscope using 
the 20x objective.  
4.2.2. Dot blotting  
Similar to the dot blotting protocol described in the previous chapter, the Low 
Fluorescence PVDF Transfer Membrane (Thermo Scientific, Rockford, IL) was cut 
approximately to 0.5 inch x 2.0 inch in size, and wet with 10 l of methanol before 
adding 0.5 - 1 l of 0.5 – 1 pmol of protein target to each spot, using 10 l round gel 
tips (USA Scientific, Ocala, FL) to obtain dots with 250 µm diameter. The membrane 
was wet with 200 µl of methanol before blocking with 500 µl of 5% skim milk in 
TBST blocking buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, and 0.005% Tween 
89 
 
20) in a 5ml clear glass dram vial for 5 minutes. Premixed IgG nanobarcodes (at 1:1 
molar ratio between IgG antibodies and ESD nanobarcodes) were added to the 
samples at 20 nM final concentrations. For multiplexed protein detection, all IgG 
nanobarcodes were added to the samples at the same time. After 6 hours of incubation, 
the membranes were washed with TBST blocking buffer 3 times, and imaged with 
Olympus BX61 fluorescence microscope using the 10x objective after drying. 
4.2.3. Western blotting (WB) 
Protein samples (GFP and HSF proteins) were boiled at 95°C for 5 minutes 
before being loaded into a 4-20% Mini-PROTEAN TGX™ Precast gel (BioRad, 
Hercule, CA)  and run with 1x SDS running buffer (250 mM Tris base, 192 mM 
Glycine, 0.1% SDS, pH 8.3) at 250 volts for 30 minutes.  Protein samples on gel were 
transferred onto a low fluorescence PVDF membrane following a standard protocol 
for western blotting at 120V for 40 min. A prestained SeeBlue Plus 2 protein ladder 
(Invitrogen, Carlsbad, CA) was used as a marker to ensure proteins were transferred 
properly to the PVDF membrane. The membrane was then blocked with 15 ml of 
blocking buffer  including 5% skim milk in TBST buffer (50 mM Tris-HCl, pH 7.4, 
150 mM NaCl, and 0.005% Tween 20) for 5 minutes at room temperature. About 30 
pmol of anti GFP IgG-DNA linker 1 (a mixture of anti GFP IgG + ESD conjugate at a 
1:1 molar ratio) and 30 pmol of anti HSF-DNA linker 3 (a mixture of anti HSF IgG + 
EZZcys-DNA linker 3 at 1:1 molar ratio) were added into the blocking buffer. The 
membrane was incubated at room temperature for overnight. After washing three 
times with TBST buffer for 3 minutes, 5 µl of 1 µM of anti-linker 1-modified quantum 
dots 605 (red) and 5 µl of 1 µM anti-linker 3-modified quantum dots 525 (green) were 
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added into the TBST buffer to hybridize with the DNA linkers 1 and 3 of the IgG 
antibodies. The samples were incubated at room temperature for 1-2 hours before 
washing three times with TBST buffer again. The membrane was dried completely 
before being imaged with the Kodak Imaging Station 4000R with red and green filters, 
and the images were processed with ImageJ software. 
4.2.4. Immunofluorescence  
The pancreas tissues of sacrificed mice were fixed in 4% paraformaldehyde 
overnight and washed three times with 1x PBS buffer, pH 7.4 and soaked in 70% 
ethanol. The fixed tissues were then dissected. After deparaffinization, fixed tissue 
slides were steamed in 0.01M citrate buffer. After washing in 0.01M PBS (pH 7.2), 50 
µl of blocking solution (1 mg/ml of salmon sperm single strand DNA (sssDNA) and 
10% normal blocking rabbit serum in 5% BSA) was applied for one hour at room 
temperature in a humid chamber. Premixed IgG nanobarcodes were prepared by 
adding IgG antibodies with ESD nanobarcodes at 1:1 molar ratios, and incubating at 
room temperature overnight. Rabbit polyclonal anti-insulin, anti-glucagon, and anti-
PDX-1 IgG antibodies (Santa Cruz Biotechnology, Santa Cruz, CA) were used in this 
work. One pmol of the corresponding IgG nanobarcodes was added to the samples in 
50 µl of blocking buffer, and incubated in a humid chamber overnight at room 
temperature. After washing for three times in 1x PBS, the samples were mounted with 
ProLong® Gold antifade reagent (Invitrogen, Carlsbad, CA). Specimens were 
examined using the appropriate excitation wavelength for each fluorophore, and the 
images were taken with the Olympus BX61 fluorescence microscope using the 20x or 
40x objectives.  
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4.3. Results 
4.3.1. Multiplexed bead-based detection 
Using a concept similar to ELISA, two different IgG antibodies, which 
recognized two different binding sites of an antigen, were used to detect a target 
protein. In this work, I used anti-His IgG antibody (Abcam, Cambridge, MA) as the 
first IgG antibody for all antigens, and chose the second IgG antibody specifically for 
each target protein. Figure 4.2A describes the general scheme of the bead-based 
protein detection strategy. Anti-His IgG-immobilized PS beads were used to bind 
protein targets before a second fluorescence-labeled IgG antibody (a complex of IgG 
antibody and ESD nanobarcodes) was added to label the beads. Anti-His IgG-
immobilized PS beads were generated by mixing the ESD conjugate with DNA-
modified PS beads (to form ESD beads) before they were bound to anti-His IgG 
antibody. Unlike direct biotinylated-IgG deposition on PS beads, using ESD beads 
enabled the generation of bead-based IgG antibodies with lower non-specific binding. 
EZZ protein specifically binds to the Fc region of IgG antibodies which prevented the 
non-specific binding between the first IgG antibodies and the unbound ESD 
nanobarcodes. As a result, in the absence of targets (Figure 4.2E), there was no 
fluorescence detected from the beads. When the targets were available, fluorescent 
beads were detected, either individually (Figures 4.2B-D) or together (Figure 4.2F). 
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Figure 4.2. Multiplexed bead-based protein detection. (A) Scheme illustrating antigen 
detection using microbead labeling. Polysterene beads were tagged with the first IgG 
antibody which captured the antigen and then sandwiched with the second IgG 
nanobarcodes. (B) GFP protein target labeled with R2G0-labeled anti-GFP IgG 
antibody. (C) Drosophila heat shock factor (HSF) protein target labeled with R0G2-
labeled anti-HSF IgG antibody. (D) Renilla Luciferase (RL) protein target labeled 
with R1G1-labeled anti-RL IgG antibody. (E) No target labeled with all three IgG 
antibodies used in samples B-D. (F) GFP, HSF, and RL protein targets labeled with 
R2G0-labeled anti-GFP, R0G2-labeled anti-HSF, and R1G1-labeled anti-RL IgG 
antibodies, respectively. 
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4.3.2. Multiplexed protein detection using a dot blotting technique 
GFP, RL and HSF proteins were again used as the targets for dot blotting 
protein detection with IgG nanobarcodes.  Different amount of target proteins, varying 
from 0.25 – 2 pmol, was spotted on low fluorescence PVDF membrane to give 250 
µm protein dots. 20 nM of IgG nanobarcodes were used to detect the proteins on the 
membrane. For single protein detection (Figure 4.3), the minimum fluorescence signal 
that could be detected ranged from 0.25 pmol (for GFP and HSF proteins) to 0.5 pmol 
(for RL protein) amount of protein targets, corresponding to 7.5-20 ng of proteins. 
Sortase proteins were included as negative controls to confirm the specificity of the 
detection. The differences in sensitivity were due to the differences in binding affinity 
and efficiency between different antigens and antibodies; this was clearer in the 
multiplexed detection of proteins when all targets were present on the same membrane 
(Figure 4.4A), and incubated with all IgG nanobarcodes at the same time. The dots 
were imaged with the Olympus BX61 fluorescence microscope using the 10x 
objective with the same exposure times. Overlay images were prepared using ImageJ 
software with consistent brightness and contrast display settings. As shown in Figure 
4.4, GFP showed much stronger binding and higher sensitivity compared to HSF and 
RL proteins. The signal was saturated at the 0.5 pmol amount of GFP protein while it 
was much weaker in the cases of 2 pmol of RL and 1 pmol of HSF proteins. 
Regardless of the big difference in fluorescence intensity of different targets, it is clear 
that multiple proteins could be detected simultaneously using this membrane-based 
system with IgG nanobarcode complexes.  
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Figure 4.3. Protein detection using the dot blotting technique. The dot size is about 
250 µm. Overlay images of the dots were achieved from the Olympus BX61 
fluorescence microscope with the 10x objective using red, green channels. From top to 
bottom row, GFP protein was labeled with R2G0-labeled anti GFP IgG, RL protein 
was labeled with R1G1-labeled anti RL IgG, and HSF protein was labeled with R0G2-
labeled anti HSF IgG antibodies. Sortase protein was used as negative controls. 
Different amounts of proteins were used to determine the limit of the detection. 
Depending on the binding affinity and efficiency, the detection limit was as low as 
0.25 pmol (GFP and HSF proteins) or 0.5 pmol (RL protein), corresponding to 7.5-20 
ng of proteins.  
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Figure 4.3. Multiplexed protein detection using the dot blotting technique. Each dot 
size is about 250 µm. A. Scheme illustrating the multiplexed protein detection. 
Different protein targets were spotted on the PVDF membrane and incubated with 
fluorescence-labeled IgG nanobarcodes to generate specific signals. B. Overlay 
images of the dots were achieved from the Olympus BX61 fluorescence microscope 
with the 10x objective using red, green channels. From left to right, GFP protein was 
labeled with R2G0-labeled anti GFP IgG, RL protein was labeled with R1G1-labeled 
anti RL IgG, HSF protein labeled was with R0G2-labeled anti HSF IgG antibodies, and 
sortase protein (which had no binding to the IgG antibodies) was used as a negative 
control.  
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4.3.3. Western Blotting (WB) detection 
Although the dot blotting (DB) technique is fast, easy and simple to detect 
proteins, it requires pure proteins as the targets and is unable to detect a protein from a 
mixture of other proteins or from protein lysates. In contrast, WBhas the advantage of 
pre-separation of proteins on a PAGE gel before the proteins are transferred to a 
PVDF membrane, which helps to overcome this limit of the DB technique. In 
particular, using a 2D gel technique, the protein separation is even better due to the 
inclusion of a secondary separation based on the total number of charges of the 
proteins, in addition to the initial separation based on molecular weight differences. 
Thus, each protein will exist on the PVDF membrane as a single band for 1D-WB or a 
unique dot for 2D-WB.  
Unfortunately, the fluorescence-labeled IgG nanobarcodes could not generate 
enough signal to be detected by the optical camera at the large scale typical for WB 
bands (about 0.5 cm x 0.1 cm)with low amounts of target (less than 50 pmol protein 
target, data not shown).  Therefore, WB requires a much stronger signal to replace the 
fluorescence dyes of the IgG nanobarcodes in order to achieve more sensitive 
detection. Luckily, quantum dots are available with about 10 times stronger 
fluorescence intensity than fluorophores, and these quantum dots can be modified with 
DNA through the streptavidin-biotin interaction. Hence, a new strategy was developed 
for the detection of proteins using the WB technique, as described in Figure 4.4A. 
Proteins were transferred to a low fluorescence PVDF membrane and incubated with 
IgG-ESD conjugate. The unbound IgG was washed, and then DNA-immobilized 
quantum dots were added to specifically hybridize with the DNA linkers on the bound 
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IgG-ESD conjugate.  
For the first attempt at using QDs for WB detection (Figure 4.4B), I used GFP 
and HSF as the targets which were labeled with QD 605 (red) and QD 525 (green), 
respectively. Although there are many types of quantum dots (QDs) available with a 
variety of emission spectra, I used two quantum dots (QD 525 and QD 605), with 
similar emission characteristics as Alexa 488 and Alexa 546 dyes, respectively, for 
WB detection due to the limited excitation and emission filters that were available. 
This emphasizes the simplicity of the DNA nanobarcode concept which requires only 
red and green dyes and filters to generate different color ratios for many distinct 
signals. Although it is not trivial and also requires a lot of purification steps, it is 
possible to create the monovalent quantum dots which contain a single DNA 
oligonucleotide per dot. These single DNA-modified quantum dots could be used as 
single dyes to replace the fluorescent dyes in the DNA nanobarcode system, 
mimicking the nanobarcode concept to generate a much more sensitive detection 
system. However, quantum dots are quite large, about 15 nm in size, which is a little 
bit bigger than Y-DNA (about 12 nm). Thus, replacing the fluorophores, small 
molecules of 20-100 atoms, with quantum dots would generate relatively giant 
complexes. This could introduce steric hindrance and reduce the binding efficiency of 
IgG antibodies to the protein targets, thus effectively reducing the sensitivity of the 
detection method. Therefore, the approach of replacing fluorophores with QDs to 
generate DNA nanobarcodes may not be a better alternative. However, for the WB 
application in particular, two different quantum dots could be sufficient to differentiate 
three, or more protein targets if we also consider the differences in sizes as an 
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indication for the target specificity.  
 
 
Figure 4.4. Multiplexed Western blotting. A. Scheme illustrating the strategy 
of using quantum dots (QDs) for western blotting (WB) detection. Protein samples 
were separated on PAGE gel before transferred to PVDF membrane which was 
incubated with IgG-ESD conjugate before DNA-immobilized QDs were added to 
generate signals. B. HSF, and GFP protein detection by QD 525 and QD 605, 
respectively. 1 and 10 are prestained SeeBlue Plus 2 protein ladders. 2-5. HSF and 
GFP proteins detection at 5, 2, 1, and 0.5 pmol, respectively. 6-7. GFP protein 
detection at 5 and 1 pmol, respectively. 8-9. HSF protein detection at 5 and 1 pmol, 
respectively.  
99 
 
4.3.4. Immunofluorescence 
To further demonstrate the versatility of IgG nanobarcode system, 
immunofluorescence staining of the islets of mouse pancreas tissues was performed, 
using Insulin, Glucagon, and PDX-1 proteins as the protein targets. Insulin proteins 
are found in the beta cells, while glucagon proteins are located in the alpha cells 
surrounding the islets, and PDX-1 proteins are only present in the nuclei of the islets. 
Thus, this is an excellent system for demonstrating the multiplexed staining ability of 
IgG nanobarcodes. As shown in Figure 4.6, Insulin proteins were beautifully stained 
with three different R2G0-, R1G1-, and R0G2-labeled IgG nanobarcodes at 20 nM 
concentrations in one step. However, for Glucagon and PDX-1 protein targets, the 
staining efficiency was lower than for Insulin proteins, as shown in Figure 4.7 A and 
B. This is likely due to the lower specificity and binding efficiency of anti Glucagon 
and anti PDX-1 compared to anti Insulin IgG antibodies. To test this hypothesis, and 
also to explore an alternative approach, quantum dots were used as the labels instead 
of using the fluorescence-labeled DNA nanobarcodes. With the power of the confocal 
microscope, at least three or four different quantum dots with distinct excitation and 
emission wavelengths can be detected together. Three different quantum dots, QD 655 
(red), QD 605 (orange) and QD 525 (green), were used to replace the R2G0-, R1G1-, 
and R0G2- DNA barcodes, respectively, to test if we could obtain improved signals. In 
addition, two different approaches were used, termed “one-step” and “two-step” 
approaches. For the one-step approach, DNA-immobilized QDs were hybridized 
directly to IgG-ESD conjugates before staining the samples. For the two-step 
approach, IgG-ESD conjugates were first incubated with the samples, and then the 
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unbound IgG was washed before it was labeled with DNA-immobilized QDs (similar 
to the WB protocol above). However, either with one-step or two-step approaches, 
only Insulin proteins were successfully labeled while Glucagon and PDX-1 did not 
give any signals at all. With the limit of IgG antibodies available due to the low 
efficiency of anti PDX-1 IgG antibody, we could only demonstrate the multiplexed 
immunofluorescence staining process with R2G0-labeled anti Glucagon IgG antibody 
and R0G2-labeled anti Insulin IgG antibody nanobarcodes together as shown in Figure 
4.7 C. Clearly, Glucagon was stained with red fluorescence signal surrounding the 
islet, and Insulin was stained with green fluorescence signals inside the islet, which 
proved that our IgG nanobarcode system could be used for multiplexed 
immunofluorescence efficiently and specifically. These results confirmed that the IgG 
nanobarcode system can become a powerful, but simple and convenient tool not only 
for immunofluorescence staining, but also any IgG antibody-based detection system. 
 
 
101 
 
 
Figure 4.6. Immunofluorescence staining of mouse pancreas islets. A. 
Autofluorescence of a blank tissue without staining. B-D. Insulin-expressed islets 
stained with R2G0-, R1G1-, and R0G2-labeled anti Insulin IgG nanobarcodes, 
respectively. 
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Figure 4.7. Immunofluorescence staining of mouse pancreas islets. A. PDX-1-
expressed islet stained with R0G2-labeled anti PDX-1 IgG antibody nanobarcode. 
White arrows showed the representative green fluorescence signals inside the nuclei 
where PDX-1 proteins are located.  B. Glucagon-expressed islet stained with R2G0- 
labeled anti Glucagaon IgG antibody nanobarcode. White arrows showed the 
representative red fluorescence signals from alpha cells surrounding the islets where 
glucagon proteins are expressed. C. Glucagon and Insulin-expressed islet stained with 
R2G0-labeled anti Glucagon IgG antibody (red) and R0G2-labeled anti Insulin IgG 
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antibody (green) nanobarcodes, simultaneously.  
4.4. Conclusions 
EZZ-SNAP-DNA conjugate was successfully developed as the universal 
adapter for interfacing both IgG antibody and DNA moieties, such as DNA 
nanobarcodes, or quantum dots, to generate a versatile IgG-based protein detection 
system which can be used in different systems; for example, bead-based assays, dot 
blotting, western blotting and immunofluorescence. Moreover, the system can be 
generated easily by simply mixing the components together without any chemical 
reactions involved. In particular, using ESD conjugate and DNA nanobarcodes to 
prelabel IgG antibodies, this helps avoidundesirable interspecies cross-activity 
between primary and secondary antibody pairs so that IgG antibodies from same 
species can be used together. This is a big advantage in multiplexed protein detection 
due to the limited availability of primary antibodies from different species. Also, the 
procedure requires fewer preparation steps, which is convenient and time efficient. 
However, since EZZ protein was engineered based on native protein A of 
Staphylococcus aureus, there are still IgG antibodies from some species that it cannot 
bind, especially from rat, goat, and sheep. However, with most of the IgG antibodies 
available from human, mouse, and rabbit, it is more than enough to choose appropriate 
IgG antibodies to perform multiplexed protein detection with this system. 
Furthermore, if necessary, EZZ protein can be easily replaced by protein G or protein 
A/G, which can bind to all IgG antibodies available, with the same concept.  
Notably, although this work has focused on the use of DNA nanobarcodes, the 
DNA linker in this system is not limited to nanobarcodes but can be expanded to any 
104 
 
DNA-modified materials, such as quantum dots, nanoparticles, carbon nanotubes, etc. 
Therefore, the IgG based protein detection system is not limited to only fluorescence-
based protein detection system, but is also applicable to other label-free methods, such 
as plasmon surface resonance based or Raman-spectroscopy-based methods, by 
utilizing the optical and electrical properties of nanoparticles and other materials. In 
conclusion, DNA-protein hybrid materials, as demonstrated here with the ESD 
conjugate, are a powerful platform for protein detection with the potential for high 
multiplexed capacity. However, in addition to these applications in protein detection, 
DNA-protein materials will also open a new direction as nanocarriers for protein 
delivery, as will be discussed in the next chapter.  
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Chapter 5: APPLICATION 2 - DNA-assisted Protein Intracellular Delivery 
System (DAPID system) 
 
 5.1.  Introduction 
Many diseases occur from alterations in the functions or overexpression of 
intracellular proteins. As a result, inhibiting those malfunctioned proteins or delivering 
their active forms to specific cells is an important goal for many medical applications, 
including cancer therapy, vaccination, regenerative medicine, and treating loss-of-
function genetic diseases.
1-4
 However, all current protein drugs target only the surface 
of the cells to trigger signaling pathways to affect the real targets downstream;
4, 5
 and 
therefore, this is a relatively indirect way to correct the functioning of the cells. In 
order to achieve more direct responses from protein targets inside cells, protein 
intracellular delivery beyond surface delivery is essential.  
Protein intracellular delivery has been intensively explored with many 
materials such as: cell penetrating peptide, proteins, peptide nucleic acid, lipids, 
polymers, and carbon nanotubes, quantum dots, and nanoparticles. However, no work 
has been done on the use of DNA for protein intracellular delivery, despite the 
excellent advantages offered by DNA such as controllability of size and structure, 
ability to interface with other chemical and biological groups, and its natural 
biocompatibility. DNA materials with the appropriate size, such as DNA spheres from 
photocrosslinker-modified building blocks, have shown the ability to enter the cells 
without DNA transfection reagents.
6-8
 Hence, I would like to investigate the capability 
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of branched DNA that was previously developed in our lab, such as Y-DNA (Y) and 
G1 generation of DL-DNA (G1), as potential nanocarriers for protein intracellular 
delivery.  
The original designs of Y-DNA and DL-DNA were such that each Y building 
block was linked to the previous ones in the same plane, and therefore, the structures 
were “flat” or 2D, which could be disadvantageous for cellular uptake. Therefore, I 
developed a different approach to form highly branched DNA scaffolds (e.g. D1 
structure) using the hybridization of long palindromic sticky ends, instead of the 
ligation of short non-palindromic sticky ends in case of DL-DNA. The new approach 
could be able to generate “3D” DNA scaffolds due to the additional 10 nucleotide 
sticky ends at the 3’-end of the Y-based oligonucleotides, which “turned” each 
building block to different angles out of the plane of the previous Y-shaped structure. 
Also, there was no modification required to achieve this highly branched scaffold, 
unlike the phosphorylation modification required for DL-DNA, or the 
photocrosslinkable groups required for ABC monomers or DNA nanospheres.  
Moreover, this approach was more convenient, faster, and resulted in higher yield and 
tunable sizes of higher structures of DNA scaffolds, compared to the well-designed 
DL-DNA structures. However, the structures of the new DNA scaffolds were less 
precisely defined, and the sizes were not uniform.  
First, different structures of branched DNA were investigated for cellular 
uptake before being selected as the carriers for proteins and IgG antibodies delivery, 
including Y, G1, D1, and others. The uptake efficiency was high with almost 100% of 
gated cells, whose contain positive fluorescence signals compare to negative controls 
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when analyzed with flow cytometry reader. However, we obtained only weak 
fluorescence signals from cells using confocal microscopy. To resolve this 
contradiction between flow cytometry and microscopy, we needed to find a way to 
increase uptake efficiency in order to see the fluorescence signals from microscope 
images. Since DNA was designed as the carrier to deliver proteins and IgG antibodies, 
we decided to use commercially available DNA transfection reagents to boost the 
uptake efficiency. As expected, these DNA transfection reagents, which have been 
developed to efficiently deliver genes and siRNA inside cells for more than 50 years, 
greatly enhanced the DNA-protein and DNA-IgG antibody intracellular uptake. For 
the first time, DNA transfection reagents were used to deliver proteins (Figure 5.1). 
This could provide a new route for protein intracellular delivery with great efficiency. 
Furthermore, our system can be easily extended to deliver multiple proteins and other 
biomarkers, as well as moieties beyond proteins including but not limited to 
nanoparticles, lipids, and polymers, as long as they are conjugated onto branched 
DNA. We believe that this DNA-assisted protein intracellular delivery (DAPID) 
system will result in a paradigm shift in drug development and delivery.  
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Figure 5.1. Scheme illustrating DNA-assisted protein intracellular delivery system 
(DAPID system). Branched DNA structures (for examples, D1, or Y) were hybridized 
with DNA-protein hybrid molecules to serve as the nanocarriers for protein and IgG 
antibody intracellular delivery. Also, using DNA transfection reagents greatly 
enhanced the efficiency of protein and IgG antibody intracellular uptake.  
 
(IgG antibody serves as a special example for proteins) 
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5.2.  Materials and methods 
5.2.1. Alexa488-labeled DNA materials formation 
All oligonucleotides were commercially synthesized by Integrated DNA 
Technologies (Coralville, Iowa). The sequences with modifications were HPLC 
purified, and the ones without modifications were standard desalting. Without further 
purification, the oligonucleotides were dissolved in TE buffer (10 mM Tris, pH=8.0, 1 
mM ethylenediaminetetraacetic acid (EDTA)) with a final concentration of 100 µM. 
 
a. Alexa488-labeled Y-DNA (Y) formation: 
Y-DNA was annealed using the program showed in Table 3.2 of chapter 3. 
Three oligonucleotide components Ya, YbG, Yc_anti linker 3 (Table 5.1) were mixed at a 
molar ratio of 1:1:1 in the annealing buffer (10 mM Tris, pH 8.0, 1 mM EDTA, and 50 
mM NaCl) with a final concentration of 10 µM for each oligonucleotide. The product 
was confirmed with 3% agarose gel electrophoresis. 
 
Table 5.1: Sequences of oligonucleotides for Y-DNA (Y) 
Name  Modification Sequences (from 5’ to 3’) 
Ya None TGGATCCGCATGACATTCGCCGTAAG 
YbG 5’-Alexa488 CTTACGGCGAATGACCGAATCAGCCT 
Yc_anti-linker 3  None AGGCTGATTCGGTTCATGCGGATCCATT
ACGGAGGTGGTTGTGGCA 
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b. Alexa488-labeled DL-DNA (G1) formation: 
G1 generation of DL-DNA included four different Y-DNA which were 
modified from previously published works.
9
 The sequences were shown in Table 5.2. 
Individual Y was formed at 10 µM final concentration with the same protocol as 
above. After that, T4 ligase enzyme was used at 0.1 U/µl concentration to link these Y 
together at 1:1:1:1 molar ratio to form G1 structure. The ligation reaction was 
conducted at room temperature for overnight. The product was confirmed with 3% 
agarose gel electrophoresis. 
 
Table 5.2: Sequences of oligonucleotides for DL-DNA (G1)  
 Name  Modification Sequences (from 5’ to 3’) 
Y1 
Y1a None TGGATCCGCATGACATTCGCCGTAAG 
Y1b 5’- Phosphorylation TGACCTTACGGCGAATGACCGAATCAGCCT 
Yc_anti-
linker 3 
None AGGCTGATTCGGTTCATGCGGATCCATTACG
GAGGTGGTTGTGGCA 
Y2 
Y2a 5’- Phosphorylation GCAATGGATCCGCATGACATTCGCCGTAAG 
Y2b None CTTACGGCGAATGACCGAATCAGCCT 
Y2c None AGGCTGATTCGGTTCATGCGGATCCA 
Y3 
Y3a 5’- Phosphorylation ATCGTGGATCCGCATGACATTCGCCGTAAG 
YbG 5’-Alexa488 CTTACGGCGAATGACCGAATCAGCCT 
Y3c None AGGCTGATTCGGTTCATGCGGATCCA 
Y4 
Y4a 5’- Phosphorylation GTCATGGATCCGCATGACATTCGCCGTAAG 
Y4b 5’- Phosphorylation CGATCTTACGGCGAATGACCGAATCAGCCT 
Y4c 5’- Phosphorylation TTGCAGGCTGATTCGGTTCATGCGGATCCA 
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c. Other Alexa488-labeled DNA scaffolds formation 
DNA scaffolds with different sizes were formed by mixing the three 
oligonucleotide components YaG-10, Yb-10, and Yc_anti linker 3 (Table 5.3) at different 
molar ratios as described in Table 5.4 with the same protocol of forming Y-DNA. The 
products were confirmed with 2% agarose gel electrophoresis.  
Table 5.3: Sequences of oligonucleotides for DNA scaffold 
Name  Modification Sequences (from 5’ to 3’) 
YaG-10 5’-Alexa488 TGGATCCGCATGACATTCGCCGTAAGCGGACGTCCG 
Yb-10 None CTTACGGCGAATGACCGAATCAGCCTCGGACGTCCG 
Yc-10 None AGGCTGATTCGGTTCATGCGGATCCACGGACGTCCG 
Yc_anti-
linker 3  
None AGGCTGATTCGGTTCATGCGGATCCATTACGGAGGT
GGTTGTGGCA 
 
Table 5.4: Different conditions of DNA scaffolds. 1 molar ratio is equal to 20 µM 
final concentration. Alexa488 dye is represented by “G” in YaG-10 sequence. 
Sample 
Molar ratios 
YaG-10 Yb-10 Yc-10 Yc_anti-linker 3 
D1 1 1 0 1 
D2 1 1 1 0 
D3 1 1 0.5 0.5 
D4 1 1 0.75 0.25 
D5 1 1 0.25 0.75 
D6 1 1 1 0.25 
D7 1 1 1 0.5 
D8 1 1 1 1 
112 
 
5.2.2. Cellular Uptake Protocol for DNA materials 
100,000 cells were plated into each well of 24-well plate with 250 ul 
Dulbecco's Modified Eagle Medium (DMEM) (Cellgro, Mediatech, Inc., Manassas, 
VA), and incubated at 37°C for overnight. The next morning, the full medium was 
removed and replaced with 150 µl of Opti-MEM medium (Invitrogen, Grand Island, 
NY). Different DNA samples were added into each well at 50 nM and 200 nM final 
concentrations depending on the experiment designs. The samples were incubated at 
37°C for about 6 hours, and then trypsinized with 170 µl of 0.2% trypsin EDTA 
(Cellgro, Mediatech, Inc., Manassas, VA) for two minutes at 37°C. 340 µl of full 
medium was then added to inhibit the trypsinization, and the cells were transferred 
into 0.5 ml eppendorf tubes, and centrifuged at 3000 rpm for 5 min. The supernatants 
were removed and the cells were resuspended in 250 l PBS for flow cytometry 
analysis immediately.  
 
5.2.3. DNA-protein complexes 
EZZcys-DNA conjugates were incubated with Alexa488-labeled DNA 
materials (Y and D1 only) in 1x PBS buffer, pH 7.4 at 1:1 molar ratio for one hour at 
room temperature to form DNA-protein complexes. The DNA-protein materials were 
delivered into cells and analyzed with flow cytometer following the cellular uptake 
protocol for DNA materials as above. DNA-protein samples were also run on 2% 
agarose gel to double check the hybridization efficiency between EZZcys-DNA 
conjugates with Y and D1 materials.  
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5.2.4. DNA-IgG antibody complexes 
EZZcys-DNA conjugates were first incubated with normal rabbit FITC-labeled 
IgG antibodies (Santa Cruz, Inc., Santa Cruz, CA) at 1:1 molar ratio in 1x PBS buffer, 
pH 7.4 at room temperature for overnight to form single stranded (ss) DNA-IgG 
antibody. In order to generate different DNA-IgG antibody materials, DNA materials, 
having complimentary sticky ends but without Alexa488 dyes, were added with 
ssDNA-IgG antibody at 1:1 molar ratio. For examples, double stranded (ds) DNA –
IgG antibody, Y-IgG antibody, and D1-IgG antibody were formed by adding a 
complimentary oligonucleotide, Y, and D1 to ssDNA-IgG antibody, respectively. The 
DNA-IgG antibody materials were delivered into cells using a DNA transfection 
reagent, Lipofectamine-2000 (Invitrogen, Carlsbad, CA), and the samples were 
analyzed with flow cytometer as described below. 
5.2.5. Cellular Uptake Protocol of DNA-IgG antibody complexes with 
Lipofectamine-2000 
100,000 cells were plated into each well of 24-well plate with 250 µl 
Dulbecco's Modified Eagle Medium (DMEM) (Cellgro, Mediatech, Inc., Manassas, 
VA), and incubated at 37°C for overnight. The next morning, the full medium was 
removed and replaced with 150 µl of Opti-MEM medium (Invitrogen, Grand Island, 
NY). DNA-IgG antibody complexes were premixed separately with Lipofectamine-
2000 as following before adding to cells.  The appropriate volume of Lipofectamine-
2000 (for examples, 0.5, 1.0, or 1.5 µl) was dissolved into 50 µl Opti-MEM medium 
and incubated at room temperature for 5 minute. At the meantime, appropriate 
amounts of DNA-IgG antibody samples were diluted into 50 µl Opti-MEM medium 
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before mixed with 50 µl of diluted Lipofectamine-2000 for 20 minutes at room 
temperature before the mixtures were added into cells. The samples were incubated at 
37
0
C for about 5 hours, and then trypsinized with 170 µl of 0.2% trypsin EDTA 
(Cellgro, Mediatech, Inc., Manassas, VA) for two minutes at 37°C. 340 µl of full 
medium was then added to inhibit the trypsinization, and the cells were transferred 
into 0.5 ml eppendorf tubes, and centrifuged at 3000 rpm for 5 min. The supernatants 
were removed and the cells were resuspended in 250 l PBS for flow cytometry 
analysis immediately.  
5.2.6. Fluorescence or Confocal microscope imaging 
50,000 cells were prepared with 10 nM of different DNA-IgG antibody complexes in 
8-well chamber slide (Thermo Fisher Scientific, NY) with 150 µl of full DMEM medium 
according to the protocol for intracellular uptake with Lipofectamine-2000. After incubated at 
37°C for 5 hours, the cells were gently washed with 1x PBS buffer, pH 7.4 for two times at 
room temperature before the supernatants were removed completely. 200 µl of 4% 
paraformaldehyde was added, and the samples were incubated at room temperature for 30 – 45 
minutes. The samples were then incubated to wash with 300 µl of 1x PBS buffer for two times 
for 5 minutes. The supernatants were removed and the cells were soaked with 200 µl of TBP 
solution (0.1% Triton X-100, 10 mg/ml BSA, and 1X PBS buffer, pH 7.4) at room 
temperature for 10 minutes. TBP solution was removed and the cells were washed again with 
1x PBS buffer for 5 minutes before stained with 200 µl of 250 nM of DAPI solution. The 
samples were protected from light and incubated at room temperature for 5 minutes before 
washed with 300 µl of 1x PBS buffer for 10 minutes. PBS buffer was removed, and the wells 
and silicon surrounding were removed from the glass slide chamber. Anti-fade reagent was 
added before the samples were sealed with the cover glass slide. Cell images were taken by 
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the Olympus BX61 fluorescence microscope with appropriate exposure times. Images of 
Zstack series from Zeiss 510 confocal microscope was obtained to prove that the DNA-IgG 
antibody complexes were truly inside the cells.  
 
5.3. Results 
5.3.1. Alexa488-labeled DNA materials  
DNA materials with well-defined structures such as Y-DNA and G1 DL-DNA 
as well as undefined structures such as DNA scaffolds were used to test the capability 
of getting inside the cells before being used as the carriers for protein delivery. Figure 
5.2a shows the relative size comparison of oligo (lane 1), Y-DNA (Y) (lane 2-3), DNA 
scaffold (D1) (lane 4-7), and DL-DNA (G1) (lane 8). Based on the sizes of Y and G1 
structures which are about 10 nm and 15 nm, respectively, we can assume that the 
sizes of D1 structures are also the same based on the similar mobility on gel. 
Moreover, several structures of DNA scaffolds (Figure 5.2b) were also formed with 
different ratios of oligonucleotide components as described on table c) to test whether 
the sizes would affect the uptake efficiency. For DNA scaffolds formation, when three 
10 base non-palindromic sticky ends were used together (D2 structure), the network 
would expand easily to form very big structures.  This behavior is similar to that of 
DNA hydrogels (data not shown). Thus, the product was mostly stuck in the well of 
the gel. When adding Yc_anti linker 3, which acted as a stopper to the polymerization 
of DNA scaffold, the structures got smaller depending on the total number of sticky 
ends available in the mixture. D1 with only two sticky ends used formed the smallest 
structure of DNA scaffold. However, although the average size could be controlled, 
the polydispersity was very high; more investigation and optimization may be needed 
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in order to reduce this variation.  
 
Figure 5.2. Relative size comparison of different DNA materials on agarose gel. DNA 
samples contained Alexa488 dye, so the images were taken directly without staining 
using a green filter.  a) 3% agarose gel electrophoresis. 1. Oligonucleotide. 2. Y-DNA 
with one anti-linker overhang. 3. Y-DNA with two anti-linker overhang. 4-7. DNA 
scaffolds (D1 structure) at 1, 20, 50, and 75 µM concentrations, respectively. 8. G1 
generation of DL-DNA. b) 2% agarose gel electrophoresis. D1-D8. DNA scaffold 
structures with different sizes were formed based on the molar ratios of 
oligonucleotide components as described in table c. D1 condition with only two 10 
base non-palindromic sticky ends gave the smallest structure, while D2 condition with 
three sticky ends gave the largest one. In addition, for an estimation of sizes of DNA 
scaffolds, D1 sample on gel b is the same as D1 sample (lane 5) on gel a.  
117 
 
5.3.2. Intracellular uptake of DNA materials  
DNA materials, including oligo, Y, G1, and some DNA scaffold structures 
(D1, D3, D4 and D6) as the representatives of different structures at different sizes 
were first tested for cellular uptake before considered as the carriers for proteins or 
IgG antibody delivery. 100,000 HeLa cells were spread in each well of 24-well plate 
and incubated overnight before Alexa488-labeled DNA materials were added and 
incubated for 6 hours at 37
o
C. Samples were washed, resuspended in 200 µl of 1x 
PBS, pH 7.4, and analyzed with BD Biosciences LSR II flow cytometry analyzer, and 
the data was analyzed by FACSDiva Software, version 6.1.1 as described in Figure 
5.3. 30,000 cells were used to be analyzed to define the uptake efficiency. Single cells 
were selected, and a gate of positive fluorescence signals was set up between cell only 
and other samples. The numbers of cells with positive fluorescence signal were 
divided to the number of singlets (single cells) to give % of gated cells (blue circle) 
which are normally used in many publications as the delivery efficiency. However, 
this information did not take into account of duplets, clusters of cells, differentiated 
cells, and especially dead cells which could be caused by materials triggering the 
apotosis cycle. Therefore, instead of using % of gated cells to reflect the efficiency of 
delivery, the numbers of cells containing positive signals were divided to 30,000 cells 
as the total cells analyzed to get the % uptake (red circle), which would more 
accurately reflect the true uptake efficiency. Moreover, it was important to look at the 
mean value of fluorescence intensity from singlets (green circle) since it reflected the 
average numbers of molecules getting inside the cells as a parameter to measure the 
efficiency of uptake. The amount of material that could be delivered inside the cells 
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depends on the material. Therefore, it is necessary to use both % uptake and mean of 
fluorescence intensity (FITC-A mean) to calculate the efficiency of intracellular 
delivery or uptake which is described in the formula, total fluorescence intensity (total 
F.I.) = % uptake x FITC mean.  
The uptake efficiency of different materials, including single stranded (ss) 
DNA, Y, G1, and four different DNA scaffolds (D1, D3, D4 and D6) was investigated 
before they were selected as the nanocarriers for protein intracellular delivery (Figure 
5.4). Surprisingly, ssDNA had a high uptake at high concentration (200 nM), but it 
reduced dramatically at lower concentration (50 nM). This high concentration 
dependence suggested that the ssDNA uptake happened nonspecifically. Besides, the 
higher generations of DNA structures with bigger sizes, such as G1, D3, D4, and D6 
showed lower uptake efficiency, unexpectedly, compared to Y and D1 structures. 
Unlike silica nanoparticles, which showed the best uptake at 50 nm size
10
, DNA 
structures seemed to be uptaken better at smaller sizes, around 10 – 20 nm instead.  Y 
and D1 structures, therefore, were chosen to be used to delivery proteins for the next 
step.   
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Figure 5.3. Flow cytometry analysis. 30,000 cells were analyzed, and positive 
fluorescence signals were collected from single cell population. The number of cells 
with positive signals was divided to total number of cells analyzed to get % uptake 
(red circle). Total fluorescence intensity was calculated by multiplying % uptake with 
fluorescence mean value (green circle) to define the efficiency of intracellular delivery 
or uptake efficiency.  
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Figure 5.4. Intracellular uptake efficiency of different DNA materials. Total 
fluorescence intensity indicated the uptake efficiency. Single stranded DNA (oligo) 
had strong nonspecific uptake at high concentration (200 nM), but dramatically 
reduced at lower concentration (50 nM). Higher generations of DNA structures (G1, 
D3, D4, and D6) with larger sizes had lower uptake efficiency, compared to Y and D1 
structures (which is around 10 – 20 nm size). Y and D1 which showed the best uptake 
among the samples were chosen to test their ability to carry proteins inside the cells. 
Error bars were calculated from 5 repeated separate experiments for cell only, oligo, 
Y, G1, and D1 samples, but only 2 repeated separate experiments for D3, D4, and D6 
samples.  
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5.3.3. Intracellular uptake of DNA-protein complexes 
Alexa488-labeled Y and D1 DNA materials were used to delivery EZZ protein 
inside HeLa cells. DNA-protein conjugates were incubated with Alexa488-labeled 
DNA materials (Y and D1 only) at 1:1 molar ratio form DNA-protein complexes for 
intracellular uptake. Flow cytometry analysis was performed to define the uptake 
efficiency. The incorporation of EZZ protein onto Y and D1 structures was confirmed 
by 2% agarose gel electrophoresis as well.   
As shown in Figure 5.5 a, almost 100% of EZZcys-DNA conjugates were 
hybridized to Y and D1 structures, based on the amount of left over Y or D1 in the 
samples (lanes 2 and 4). Moreover, as a preliminary test, EZZ-SNAP-DNA conjugate 
was also used together with EZZcys-DNA conjugate to form a DNA-protein complex 
of one Y and two proteins (lane 3). The purpose of this sample was to see if multiple 
proteins could be delivered inside the cells using branched DNA structures. Although 
the incorporation efficiency of two proteins onto one Y was not as good as one protein 
and one Y, it still showed that we were able to form a two (or three) protein-DNA 
complex for multiplexed protein detection. Moreover, higher sequence specificity of 
different sticky ends of Y or branched structures could be designed in order to get 
higher hybridization efficiency of multiple DNA-protein conjugates with branched 
DNA.  
Protein-DNA complexes were then delivered into HeLa cells for 6 hours at 
37oC before analyzed with flow cytometry reader, similar to the procedures described 
for the intracellular uptake of DNA materials above. The images on the left hand of 
Figure 5.5 b showed the flow cytometry data of some representative samples, for 
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examples of cell only, Y-EZZ and D1-EZZ samples at 200 nM concentrations. 
Clearly, the protein-DNA complexes were uptaken by cells to give a clear shift when 
compared with cell only sample. For the quantitative data analysis, total fluorescence 
intensity (T.F.I.) was calculated and graphed as shown in the chart on the right-hand 
side. Based on T.F.I. value, the uptake of DNA-protein complexes (about 45,000-
50,000 a.u.) was about half of that of DNA only (about 80,000 - 90,000 a.u.) although 
the % of gated cells appeared to be almost 100%. This indicated that the number of 
DNA-complexes getting inside the cells was about half that of DNA only so that 
FITC-A mean value reduced half. This is expected since the incorporation of protein 
onto DNA should have introduced some charge effects that interfered with the 
intracellular uptake efficiency. In addition, the bigger sizes of the DNA-protein 
complexes could have affected the uptake efficiency since we have known that cells 
did not uptake well the bigger DNA structures (such as G1, D3, D4, and D6) as 
concluded above.  
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Figure 5.5. Intracellular uptake of DNA-protein complexes. a) confirmation of DNA-
protein complexes on 2% agarose gel. 1. Y DNA only. 2. Y + EZZcys-DNA 
conjugate. 3. Y + EZZcys-DNA and EZZ-SNAP-DNA conjugates. 4. D1 DNA only. 
5. D1 + EZZcys-DNA conjugate. b) on the left side, flow cytometry data on % of 
gated cells of some representative samples. The % of cells with positive fluorescence 
signals appeared to be almost 100%. However, the total fluorescence intensity was 
about only half, which indicated that the number of DNA-protein complexes getting 
inside the cells reduced half, when compared to that of DNA uptake only. 
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5.3.4. Intracellular uptake of DNA-IgG antibody complexes with 
Lipofectamine-2000 
Although flow cytometry data showed a clear shift in fluorescence signals 
between cells with and without DNA-protein complexes, we were unable to obtain 
fluorescence microscope images with strong fluorescence signals to confirm the 
results. In order to enhance the uptake efficiency of DNA-IgG antibody, 
Lipofectamine-2000, a DNA transfection reagent, was used. Different DNA-IgG 
antibody materials were generated by mixing FITC-labeled IgG antibodies with 
EZZcys-DNA conjugate and DNA materials (oligonucleotide, Y, and G1) at 1:1:1 
molar ratios. The DNA-IgG antibody materials were delivered into cells and analyzed 
with a flow cytometry reader to compare the efficiency of protein intracellular 
delivery. Besides, instead of using Alexa488-labeled DNA to generate fluorescence 
signals for flow cytometry analysis, the fluorescence signals now will be read directly 
from FITC dye of IgG antibodies. This helps to avoid the problem of getting positive 
signals from DNA materials getting inside the cells, but without proteins or IgG 
antibodies due to the low hybridization yield between DNA and DNA-IgG antibody 
products. The intensity of fluorescence signals in this case will truly reflect the 
number of IgG antibodies existed inside the cells so that it can be used to directly 
compare the uptake efficiency among the samples.  
First, different amounts of Lipofectamine-2000 were used to define the best 
efficiency since one of the problems of using DNA transfection reagent is that it can 
kill a lot of cells if overused, which will affected the overall efficiency of uptake. 
Three different volumes, 0.5, 1, and 1.5 µl of Lipofectamine-2000 were used to test 
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the uptake efficiency of Y-IgG and D1-IgG samples at 10 and 50 nM. Cells only with 
DNA samples, but with the same amount of Lipofectamine-2000 were used as 
negative controls. Also, samples without Lipofectamine-2000 were used to compare 
the uptake efficiency. As expected, the uptake efficiency of the samples with 
Lipofectamine-2000 was much higher compared to that without Lipofectamine-2000, 
and it reduced with less amount of Lipofectamine-2000 used (Figure 5.6).  
 Since Lipofectamine-2000 greatly enhanced the intracellular uptake efficiency, 
we wondered if branched DNA would have any advantage over linear DNA since 
DNA transfection reagents were developed for genes (linear DNA), and siRNA (linear 
RNA). Therefore, we used the best uptake condition above, which is at 50 nM 
materials with 1.5 µl of Lipofectamine, to test the efficiency of different materials, 
including, cell only, IgG only, single stranded (ss) DNA-IgG, double stranded (ds) 
DNA-IgG, Y-IgG, and D1-IgG (Figure 5.7). The same set of samples but without 
Lipofectamine was used as controls. Clearly, Lipofectamine overpowered the uptake. 
Also, branched DNA (Y and D1) have shown much better yield compared to linear 
DNA (ss and ds). This could be due to branched DNA having more accessibility to 
Lipofectamine, a cationic lipid, which could enable the transfection complexes 
between Lipofectamine and branched DNA to enter the cells through endocytosis 
more efficiently.   
As mentioned before, Lipofectamine could be toxic to the cells, so the MTT 
cell viability assay was conducted to determine the toxicity of Lipofectamine as well 
as that of DNA-protein hybrid molecules. The samples were prepared at 50 nM of 
materials with or without 1.5 µl at 37
o
C for 5h. The same samples without 
126 
 
Lipofectamine were used as controls, and the data was normalized to cell only without 
Lipofectamine. As shown in Figure 5.8, Lipofectamine itself at 1.5 µl was not toxic to 
cells, and DNA-protein hybrid materials also showed low cytotoxicity.  
Furthermore, fluorescence microscope images (Figure 5.9) were obtained to 
confirm the flow cytometry data that DNA-protein materials were delivered to cells 
with high efficiency. Moreover, z-stack series of confocal microscope images were 
also confirmed that the materials were actually delivered inside the cells (data not 
shown). In addition, endocytosis mechanism of cellular uptake for branched DNA-
protein materials with Lipofectamine-2000 was confirmed with samples prepared at 
37
o
C and 4
o
C (Figure 5.10).  
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Figure 5.6. Effects of Lipofectamine-2000 on branched DNA-IgG antibody 
intracellular delivery. Y-IgG and D1-IgG samples were delivered inside the cells for 
5h at 37
o
C. +0.5, +1.0, +1.5 indicated the volume of Lipofectamine-2000 used in the 
samples. The upper graphs showed some representative flow cytometry data of Y-IgG 
and D1-IgG without and with 1.5 µl of Lipofectamine, which showed a strong effect 
of Lipofectamine in the cellular uptake. The chart below showed different efficiency 
of cellular uptake depending on the amount of Lipofectamine used. Clearly, the uptake 
efficiency was greatly enhanced with Lipofectamine. In addition, the effects are 
stronger and different between 10 and 50 nM concentrations when more volume of 
Lipofectamine was used (+1.5 µl). The error bars were obtained from 3 separate 
experiments. 
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Figure 5.6. DNA-assisted IgG antibody intracellular delivery with Lipofectamine-
2000. The IgG antibody materials were incubated with HeLa cells at 50 nM with or 
without 1.5 µl of Lipofectamine for 5h at 37
o
C. Branched DNA-IgG complexes (Y-
IgG, D1-IgG) showed much better uptake compared to linear DNA (ssDNA-IgG, ds-
IgG). Some representative flow cytometry data of samples with Lipofectamine are 
shown in the right handed side graphs. The error bars were obtained from 3 separate 
experiments. 
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Figure 5.8. Cytotoxicity of Lipofectamine-2000 and DNA-protein materials to 
cells. 1.5 µl of Lipofectamine was used with 50 nM of materials at 37
o
C for 5h. MTT 
assay was performed, and the data was normalized to cell only without Lipofectamine. 
Lipofectamine-2000 itself at 1.5 µl is not toxic to cells when compared to cell only 
without Lipofectamine. DNA-protein hybrid materials also have low cytotoxicity. The 
error bars were obtained from 3 separate experiments. 
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Figure 5.9. Fluorescence microscope images of DNA-assisted IgG antibody delivery 
with Lipofectamine-2000. 10 nM of materials were used with 1.5 µl of Lipofectamine 
at 37
o
C, 5h. Clearly, the images confirms flow cytometry results that branched DNA-
protein can deliver proteins intracellulary in high efficiency. Also, Zstack series of 
images from confocal microscope confirmed that the IgG antibodies are inside the 
cells (data not shown). 
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Figure 5.10. Endocytosis is the main uptake mechanism of branched DNA-protein 
complexes with Lipofectamine.  
 
5.4. Conclusions 
Branched DNA (Y, and D1) has proved to be very efficient in protein 
intracellular delivery with DNA transfection reagents such as Lipofectamine-2000. In 
particular, since EZZ protein can bind to almost all IgG antibodies, the system can be 
easily extended to IgG antibody intracellular delivery. Using DNA-protein 
conjugation methods, any proteins now can be delivered efficiently inside the cells 
with the support of DNA transfection reagents. Besides, branched DNA allows 
multiple proteins to be delivered simultaneously. Furthermore, not only proteins, but 
any moieties which can be attached with DNA can be delivered inside cells also, for 
example, lipids, polymers, gold nanoparticles, etc. This novel approach may lead to 
the new discovery of drugs and treatments for currently uncured diseases due to the 
limitations of current delivery methods.  
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Chapter 6: Conclusions and Future directions 
 
6.1. Accomplishments 
Three methods, SNAP tag, sulfo-SMCC, and sortase A, were successfully used 
to conjugate DNA and proteins together without any loss of function in either the 
protein or DNA. The conjugation between DNA and EZZ proteins (such as EZZ-
SNAP-DNA (ESD) and EZZcys-DNA conjugates) served as universal adapters to 
interface between DNA and IgG antibodies, affording the construction of versatile 
platforms for IgG antibody-based protein detection and IgG antibody intracellular 
delivery.  
For multiplexed protein detection, IgG antibody-based DNA nanobarcodes 
(IgG nanobarcodes) have been successfully used to detect proteins efficiently and with 
high specificity across different systems, such as microbead-based assays, dot blotting, 
and immunofluorescence staining. In addition, by using DNA-modified quantum dots 
instead of DNA nanobarcodes, the complexes could be used to detect proteins from 
western blotting as well. Similar to prelabeled primary IgG antibodies, the IgG 
nanobarcode system gives a convenient approach to detect proteins with fewer steps in 
the procedure, while maintaining high efficiency and specificity. Moreover, IgG 
nanobarcodes can be generated in a one-pot reaction, simply by mixing individual 
components (IgG antibodiess, ESD conjugate, and DNA nanobarcodes) at 1:1:1 molar 
ratio – a significantly easier and simpler approach compared to the procedures to 
prepare prelabeled primary IgG antibodies.  
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For the first time, branched DNA (Y, D1 structures) has been used as a 
platform to deliver proteins and IgG antibodies intracellularly with high efficiency.  
 
6.2. Limitations and Future directions 
Since the EZZ protein cannot bind to some IgG antibodies, the choice of 
antibodies that can be used in IgG-based protein detection and delivery is somewhat 
limited. For protein detection, DNA nanobarcodes are not sensitive enough to have 
signals detected by western blotting. Quantum dots with much stronger fluorescence 
intensity and stability can be used to replace fluorescence dyes, but it requires 
complicated and expensive systems for signal read-out; for example, filters with 
narrower bandwidths can be utilized in the detection system in order to utilize the 
multiplexing capacity. Monovalent DNA-modified quantum dots can be used in place 
of the fluorophores in DNA nanobarcodes but their synthesis is not a trivial process. 
Besides, quantum dots are relatively large (about 15 nm) which may not suitable to 
replace small fluorophore molecules (20-100 atoms) due to steric hindrance effects.  
Nevertheless, the main goal of this work is to develop DNA as a material 
platform for interfacing with proteins. In spite of advances in protein synthesis and 
engineering, there has yet to be a general customizable approach towards adding 
functionality onto proteins in a modular fashion. DNA, on the other hand, has been 
engineered as a material for a broad range of applications due to excellent control over 
its size, structure and anisotropicity. Here, we have developed a convenient approach 
to interface DNA with proteins, thus affording the ability to modify proteins and IgG 
antibodies without resorting to protein engineering techniques that requires skilled 
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personnel. Proteins and IgG antibodies now can be labeled with fluorophores, 
quantum dots, nanoparticles, or any moieties that can be modified with DNA, in a 
single mixing step, requiring no chemical reactions. Besides, proteins can be arranged 
in a specific configuration by DNA either on microarrays or rationally designed 
structures by incorporating novel structures made available through DNA 
nanotechnology. Moreover, we envision that new proteins with desired functions can 
be engineered by bringing different protein domains together using DNA as a linker. 
We expect that this approach will open up new avenues for engineering proteins 
without going through complicated steps or relying on the predictions of amino acid 
sequences to tertiary structures to functions of proteins.  
 Furthermore, with the demonstration of the versatility of IgG nanobarcode 
systems, DNA-protein conjugate provided a platform not only for fluorescence-based 
protein detection system, but it can also be expanded to other detection systems such 
as label-free, using optical and electrical properties of gold nanoparticles. Similarly, 
for the development of protein delivery, or for the discovery of new drugs, protein 
drugs now will not stand alone in the battle of uncured diseases. With the interfacing 
of DNA and the supports from other DNA nanotechnology, protein drugs can be 
combined with any other moieties such as lipid, polymers, nanoparticles, etc. to create 
“super” drugs. More importantly, the drugs will not just target at the surface of the 
cells, which all current protein drugs do, but they will be delivered efficiently inside 
the cells using DNA transfection reagents which are well developed for more than 50 
years, and some are FDA-approved. We are optimistic that the development of this 
technology will pave the way for a future of DNA-based protein engineering, where 
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malfunctioned proteins inside the cells can be replaced with the healthy ones to set up 
again the normal functions of the cells without guessing or relying on signaling 
pathways to judge the effects of new drugs.  
 
 
